Title of Invention	A METHOD OF PRODUCING AN ANTIFREEZE PROSTEIN
Abstract	A method of obtaining an anti-freeze protein having the amino acid t sequence D-E-Q-P-N-T-I-S-G-S-N-N-T-V-R-S-G-S-K-N-V-L-A-G-N-D-N-T-V-I-S-G-D-N-N-S-V-S-G-S-N-N-T-V-V-S-G-N-D-N-T-V-T-G-S-N-H-V-V-S-G-T-N-H-I-V-T-D-N-N-N-N-V-S-G-N-D-N-N-V-S-G-S-F-H-T-V-S-G-G-H-N-T-V-S-G-S-N-N-T-V-S-G-S-N-H-V-V-S-G-S-N-K-V-V-T-D-A (SEQ ID NO: 1), or having an amino aoid sequence having at least 80% overlap with SEQ ID NO: 1, the method comprising providing a nucleic acid vector comprising a polynucleotide that encodes the AFP in a suitable host organism and expressing the AFP from the vector, or isolating the AFP from a cold-acclimatised grass.

Title of Invention

A METHOD OF PRODUCING AN ANTIFREEZE PROSTEIN

Abstract

A method of obtaining an anti-freeze protein having the amino acid t sequence D-E-Q-P-N-T-I-S-G-S-N-N-T-V-R-S-G-S-K-N-V-L-A-G-N-D-N-T-V-I-S-G-D-N-N-S-V-S-G-S-N-N-T-V-V-S-G-N-D-N-T-V-T-G-S-N-H-V-V-S-G-T-N-H-I-V-T-D-N-N-N-N-V-S-G-N-D-N-N-V-S-G-S-F-H-T-V-S-G-G-H-N-T-V-S-G-S-N-N-T-V-S-G-S-N-H-V-V-S-G-S-N-K-V-V-T-D-A (SEQ ID NO: 1), or having an amino aoid sequence having at least 80% overlap with SEQ ID NO: 1, the method comprising providing a nucleic acid vector comprising a polynucleotide that encodes the AFP in a suitable host organism and expressing the AFP from the vector, or isolating the AFP from a cold-acclimatised grass.

Full Text	FORM 2 THE PATENTS ACT,1970 ( 39 of 1970 ) COMPLETE SPECIFICATION SECTION 10 TITLE "A METHOD OF PRODUCING AN ANTIFREEZE PROTEIN" APPLICANT HINDUSTAN LEVER LIMITED, a Company incorporated under the Indian Companies Act, 1913 and having its Registered Office at Hindustan Lever House, 165/166 Backbay Reclamation, Mumbai 400 020, Maharashtra, India The following specification particularly describes the nature of the invention and the manner in which it is to be performed WO 99/37782 PCT/EP98/08553 "A method of producing an anti freeze protein" 5 Technical Field of the Invention The invention relates to anti-freeze proteins (AFPs) and frozen food product containing AFPs. 10 Background to the Invention Anti-freeze proteins (AFPs) have been suggested for improving the freezing tolerance of foodstuffs. 15 For the purpose of the invention, the term AFP has the . meaning as well-known in the art, namely those proteins which exhibit the activity of inhibit the growth of ice crystals. See for example US 5/118,792. 20 WO 90/13571 discloses antifreeze peptides produced chemically or by recombinant DNA techniques. The AFPs can suitably be used in food-products. Example 3B shows modified ice crystal shapes if a water-ice mixture is frozen into a film in combination with 0.01 wt% of AFP. 25 WO 92/22581 discloses AFPs from plants which can be used for controlling ice crystal shape in ice-cream. This document also describes a process for extracting a polypeptide composition from extracellular spaces of plants 30 by infiltrating leaves with an extraction medium without rupturing the plants. WO 94/03617 discloses the production of AFPs from yeast and their possible use in ice-cream. WO 96/11586 describes fish WO 99/37782 PCT/EP98/08S53 AFPs produced by microbes. Several literature places also mention the isolation and/or use of plant proteins for cryoprotection. Cryoprotective 5 proteins have a function in the protection of plant membranes against frost damage. These proteins, however, do not possess recrystallisation inhibition properties and are, therefore, not embraced within the terms AFPs. 10 Hincha in Journal of Plant Physiology, 1992, 140, 236-240 describes the isolation of cryoprotective proteins from cabbage. Volger in Biochimica et Biophysica Acta, 412 (1975), 335-349 describes the isolation of cryoprotective leaf proteins from spinach. Boothe in Plant Physiol (1995), 15 108: 759-803 describes the isolation of proteins from Brassica napus. Again, these proteins are believed to be cryoprotective proteins rather than AFPs. Neven in Plant Molecular Biology 21: 291-305, 1993 describes the DNA characterisation of a spinach cryoprotective protein. 20 Salzman in Abstracts and Reviews of the 18th Annual Meeting" of the ASEV/Eastern Section in Am. J. Enol. Vitic, Vol. 44, No. 4, 1993 describes the presence of boiling-stable polypeptides in buds of Vitis. Although the proteins are analogous to fish antifreeze peptides, they are 25 cryoprotective proteins and not AFPs. Lin in Biochemical and Biophysical Research Communication, Vol. 183, No. 3, 1992, pages 1103-1108 and in Lin, Plant Physiology (1992) 99, 519-525 describes the 15 kDa cryoprotective polypeptide from Arabidopsis Hakaira, Houde in The Plant Journal (1995) 30 8(4), 583-593 mentions cryoprotective proteins from wheat. Up till now, however the use of AFPs has not been applied to commercially available food products. One reason for WO 99/37782 PCT/EP98/08553 this are the high costs and complicated process for obtaining AFPs. Another reason is that the AFPs which until now have been "suggested for use in frozen food products cannot be incorporated in the standard formulation mix, 5 because they tend to destabilise during processing especially during the pasteurisation step. This destabilisation is believed to be caused by the denaturation of the AFPs; this is a well-known effect commonly observed for peptides and proteins. 10 In our non pre-published patent application: PCT/EP97/03634 it has been described that AFPs can be isolated from natural sources such as cold-acclimatised grass by means of Via new relatively simple process. This process leads for the 15 first time to the identification of AFPs which can conveniently be incorporated in a mix for the preparation of frozen products before the pasteurisation thereof. This process for the recovery of AFPs from grass involves 20 the steps of a) isolating a AFP containing juice from the grass; b) heat treating the grass or the AFP containing juice to a temperature of at least 60°C; c) removing the insoluble fraction. 25 Step c of the above process will usually take place after steps a and b. Step a and b can be done in any desired order, for example step a followed by step b (in that case the AFP rich juice will be heated) or step b followed by 30 step a (in that case the natural source will be heated) or step a and b simultaneously. This process has a number of advantages. Firstly by using the process it is no longer necessary to avoid rupturing of WO 99/37782 PCTYEP98/08553 10 15 the grass such as required in the processes according to WO 92/22581. This immediately significantly increases the commercial applicability of the process, for example as compared to WO .92/22581, because high investment costs for specific processing are no longer necessary. Also by using the high temperatures it seems possible to extract from a large group of peptides present in the grass a very active AFP which is very active w.r.t. ice-recrystallisation inhibition properties. Thirdly, contrary to expectations, the use of high temperatures does not denature all the proteinaceous material, but does only seem to denature some of; the proteins, while the remaining grass AFP have an increased temperature stability. This renders it possible to include the isolated AFPs in compositions which need to be subjected to higher temperatures e.g. a pasteurisation step. This is especially surprising, because for example the AFPs from WO 92/22581 appear not stable under heating conditions. 20 The process as described above includes in step b the . heating of the grass or the AFP rich juice to a temperature of more than 60°C. Preferably the temperature is from 60 to 110 °C, most preferably from 80 to 105oc. The heating step can take place after the isolation of the protein rich 25 juice (step a) or before the isolation of the protein rich juice. Any suitable way to heat the juice can be used, for example conventional or microwave heating, heating optionally with an added extraction medium, steaming etc. 30 If an extraction medium is used, preferably it is used in small volumes to avoid unnecessary dilution of the AFP fraction. Any suitable extraction medium can be used, although the use of water is especially preferred. If desired, additives may be added to the water prior to using WO 99/37782 PCT7EP98/08553 it as an extraction medium. Most preferred, however water substantially free of additives is used. Applicants have also found that by the above process a-very 5 active AFP derived from grass can be derived. For the purpose of the invention the term grass encompasses members of the Graroineae family including for example perennial grass such as Lolium perenne, Parapholis strigosa, Nardus stricta, Catapodium loliaceum and Lolium multiflorum, Poa 10 trivialis, Poa pratensis and cereal crops such as winter rye, winter wheat and winter barley. Applicants have determined the amino acid sequence of this AFP. Surprisingly it has been found that very active AFPs which 15 can be derived from plants are characterised by a high level of the amino acids: Serine (S), Threonine (T) and Asparagine (N)• In particular applicants have found that preferred AFPs of the invention are characterised in that at least 40% of the amino acids in the protein are selected 20 from S, T and N- Preferably the AFPs are derived from grasses, especially the Gramineae family. The preferred molecular weight of AFPs of the invention is form 8 to 16 kDa, more preferred 10-14 kDa, where this 25 molecular weight is determined from the gene sequence or by mass spectrometry of the unmodified form e.g. in unglycosylated form. A second aspect of the invention relates to an AFP which 30 can be derived from grass, said AFP having an amino acid sequence from the N-terminus of: WO 99/37782 PCT/EP98/085S3 D-E-Q-P-N-T-I-S-G-S-N-N-T-V-R-S-G-S-K-N-V-L-A-G-N-D-N-T-V- I-S-G-D-N-N-S-V-S-G-S-N-N-T-V-V-S-G-N-D-N-T-V-T-G-S-N-H-V-5 V-S-G-T-N-H-I-V-T-D-N-N-N-N-V-S-G-N-D-N-N-V-S-G-S-F-H-T-V- S-G-G-H-N-T-V-S-G-S-N-N-T-V-S-G-S-N-H-V-V-S-G-S-N-K-V-V-T- 10 D-A Also embraced in the scope of our invention are proteins having a sequence which has a high degree of similarity with the above sequence. For the purpose of the invention 15 all RI active proteins having an amino acid sequence of at least 80% overlap with the above sequence are also embraced in the scope of the invention. More preferred is an overlap of at least 90%, most preferred more than 95%, e.g. those amino acid sequences which differ none or only one or two 20 amino acids with the above sequence. Also isoforms of the above protein are embraced within the invention. Also embraced within the scope of the present invention are modified versions of the above described proteins whereby 25 said modification does not materially affect the ice recrystallisation inhibition properties, such as glycosylated versions thereof. The AFP rich juice can be. separated from the grass by any 30 convenient process for example pressing, filtering, homogenising, extraction etc. Preferably the grass is made into small pieces or into a slurry before the protein rich fraction is collected, for example by filtering. This maceration can be done by any suitable method, for example WO 99/37782 PCT/EP98/08553 in a blender. It will be well within the ability of the skilled person to divide the material into such a form that collection of the protein rich juice can readily take place.. 5 After collecting and heating (in the desired order), the protein fraction the resulting AFP containing sample can then be treated by any convenient process in order to remove the insoluble fraction and retain the AFP rich 10 liquid fraction. The insoluble fraction can be removed e.g. by filtering, precipitation etc. The AFP rich liquid can then advantageously be further processed to concentrate or isolate the AFPs to bring them in a form suitable for further use. Examples of suitable processes are drying to 15 obtain a powder or paste, further concentration to obtain an AFP concentrate, chromatography to separate the AFPs from the extraction medium etc. Again it will be well within the ability of the skilled person to determine the suitable means and conditions for appropriate isolation. 20 Applicants have also determined the nucleic acid sequence that encodes the above described AFP. Accordingly a second aspect of the invention relates to a nucleic acid sequence capable of encoding for the AFPs of the invention. 25 Preferably said nucleic acid has the sequence of: WO 99/37782 PCT/EP98/08SS3 GAT GAA CAG CCG AAT ACG ATT TCT GGG AGC AAC AAT ACT GTC AGA TCC GGG AGC AAA AAT GTT CTT GCT GGG AAT GAC AAC ACC GTC ATA 5 TCT GGG GAC AAC AAT AGT GTG TCT GGG AGC AAC AAC ACT GTC GTA AGT GGG AAT GAC AAT ACC GTA ACC GGC AGC AAC CAT GTC GTA TCA GGG ACA AAC CAT ATC GTT ACA GAC AAC AAC AAT AAC GTA TCC GGG AAC GAT AAT AAT GTA TCC GGG AGC TTT CAT ACC GTA TCC GGG GGG CAC AAT ACT GTG TCC GGG AGC AAC AAT ACC GTA TCT GGG AGC AAC 10 CAC GTT GTA TCT GGA AGC AAC AAA GTC GTG ACA GAC GCT TAA Also embraced within the scope of the present invention are alleles or other nucleic acid sequences which are capable to encode the above described AFPs, for example those 15 nucleic acid sequences wherein wrt the above sequence one or more codons have been replaced by their synonyms (i.e. codons encoding for the same amino acid). Vectors containing a nucleic acid sequence capable of 20 encoding the AFP of the invention are also embraced within the scope of the invention. Based on the above information it is also possible to genetically modify other natural sources such that 25 they produce the advantageous AFP as identified here-above. Applicants also have found that AFPs of the above sequence have improved ice-recrystallidation inhibition properties. A suitable test for determining the ice recrystallisation 30 inhibition properties is described in the examples and involves the quick freezing to -40oc followed by storage WO 99/37782 PCT/EP98/08553 for one hour at -60c. Preferably AFPs which are subject to this test after heat-treatment result in an ice crystal particle size which is less than 5 μm larger than the ice crystal size of a sample with the same AFP which was not 5 heat-treated, preferably the difference is less than 3 urn, most preferred less than 1 μm. Preferably those AFPs are chosen which have significant ice-recrystallisation inhibition properties. A suitable 10 test for determining the recrystallisation inhibition properties is indicated in the examples. Preferably AFPs in accordance to the invention provide a ice particle size following an ice recrystallisation inhibition assay -as described in the examples- of 15 μm or less, more preferred 15 from 5 to 15 μm. The AFP of the invention can conveniently be used in food products, preferably in food products which are frozen or intended to be frozen. Especially preferred is the use of 20 AFPs in products which are heated e.g. by pasteurisation, blanching or sterilisation prior to freezing. Especially preferred is the use in frozen confectionery products. Examples of such food products are: frozen confectionery 25 mixes such as ice-cream mixes and water-ice mixes which are intended to be pasteurised prior to freezing. Such mixes are usually stored at ambient temperature. Suitable product forms are for example: a powder mix, which is packed for example in a bag or in sachets. Said mix being capable of 30 forming the basis of the frozen food product e.g. after addition of water and optionally other ingredients and -optional- aeration. WO 99/37782 PCT/EP98/085S3 Another example of a suitable mix could be a liquid mix (optionally aerated) which, if necessary after addition of further components and optional further aeration can be frozen. 5 The clear advantage of the above mentioned mixes is that the presence of the AFP ingredient makes that the mixes can be frozen under quiescent conditions, for example in a shop or home freezer without the formation of unacceptable ice 10 crystal shapes and hence with a texture different to products normally obtained via quiescent freezing. Very conveniently these mixes are packed in closed containers (e.g. cartons, bags, boxes, plastic containers 15 etc) . For single portions the pack size will generally be from 10 to 1000 g. For multiple portions pack sizes of up to 500 kg may be suitable. Generally the pack size will be from 10 g to 5000 gl 20 As indicated above the preferred products wherein the AFPs are used are frozen confectionery product such as ice-cream or water-ice. Preferably the level of AFPs is from 0.00001 to 0.5 wt% based on the final product. If dry-mixes or concentrates are used, the concentration may be higher in 25 order to ensure that the level in the final frozen product is within the above ranges. For the purpose of the invention the term frozen confectionery product includes milk containing frozen 30 confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees. For some applications the use in fermented food products is less preferred. WO 99/37782 PCT/EP98/08553 Preferably a the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 4 wt%, for example more than 30 wt%, more preferred from 40 to 70wt%. 5 Frozen confectionery products according to the invention can be produced by any method suitable for the production of frozen confectionery. Especially preferably however all the ingredients of the formulation are fully mixed before pasteurisation and before the freezing process starts. The 10 freezing process may advantageously involve a hardening step, for example to a temperature of -30 Celsius or lower. WO 99/37782 Example I Isolation of AFPs by first heating grass, followed by isolating the AFP rich juice and isolation of the AFP. Mixed grass tissue (Poa Trivialis, Lolium Perenne, Holcus Lanatus, Bromus Sterilis) was cut in January (mean temperature in that month was 3.5 °C ensuring the appropriate cold acclimatization of the plants). The grass 10 tissue was rapidly transported into the laboratory for further handling and washed thoroughly with water to remove dirt. 500 g of grass clippings was placed in a 650 Watt microwave 15 oven and heated at full power for 5 minutes, whereby the temperature was raised to 85 to lOOoC. The grass clippings were then cooled to ambient temperature. Alternatively the grass clippings are mixed with 500 g 20 boiling water and the mixture is re-heated to 100 °C followed by boiling for 10 minutes under stirring and then allowed to cool to 60 °C. After the heating step the AFP rich juice was separated 25 from the clippings by filtering. The mass was stirred continuously for 5 minutes in the presence of an equal volume of water and then squeezed through 3 layers of muslin. 30 The supernatant can be freeze dried to remove the water followed by storage. Alternatively the supernatant can be frozen for storage. WO 99/37782 PCT/EP98/08553 Example II A liquid premix for the preparation of ice-cream was prepared by mixing: 5 Ingredient % by weight Skimmed milk powder 10.00 sucrose ,13.00 maltodextrine (MD40) 4.00 10 Locust bean gum 0.14 butter oil 8.00 monoglyceride (palmitate) 0.30 vanillin 0.01 AFP (of example I) 0.01 or none (control) 15 water balance Note: AFP is added as concentrated AFP solution in some of the water, percentage refers to amount of AFP. 20 The ingredients were mixed at ambient temperature followed by pasteurisation for 60 seconds at 89°C. The mix was aseptically filled into packs of 500 ml, sealed and stored at ambient temperatures. 25 The mix can be used for the preparation of ice-cream by whipping it with a conventional house-hold mixer to an overrun of about 70 % followed by freezing under quiescent conditions in a house-hold freezer. 30 After two months storage the composition according to the invention had a markedly better texture than the control sample. WO 99/37782 PCT/EP98/08553 Example III The ice recrystallisation inhibition properties of the AFPs can determined as follows: 5 A sample of an AFP containing product was adjusted to a sucrose level of 30 wt% (If the starting level of the sample was more than 30% this was done by dilution, if the starting level was lower sucrose was added to the 30% 10 level). A 3 μL drop of the sample was placed on a 22 mm coverslip. A 16 mm diameter cover-slip was then placed on top and a 200 g weight was placed on the sample to ensure a uniform 15 slide thickness. The edges of the coverslip were sealed with clear nail varnish. The slide was placed on a Linkham THM 600 temperature controlled microscope stage, the stage was cooled rapidly 20 (50 oC per minute) to -40°C to produce a large population of small crystals. The stage temperature was then raised rapidly (50oc per minute) to -6 °C and held at this temperature. 25 The ice-phase was observed at -6 oC using a Leica Aristoplan microscope. Polarised light conditions in conjunction with a lambda plate were used to enhance the contrast of the ice crystals. The state of the ice phase (size of ice crystals) was recorded by 35 mm 30 photomicrography at T=0 and T=l hour. Generally this test can be applied to any suitable composition comprising AFP and water. Generally the level of AFP in such a test composition is not very critical and WO 99/37782 PCT/EP98/08553 can for example be from 0.0001 to 0.5 wt%, more preferred 0.0005 to 0.1 wt%, most preferred 0.001 to 0.05 wt%, for example 0.01 wt% 5 Any suitable composition comprising AFP and water can be used to carry out the test. Generally, however, it will not be necessary to obtain the AFP in purified form. For practical applications normally it would suffice to prepare a liquid extract or juice of natural material, wherein this 10 extract or juice can then be tested. This method can be applied for example to the AFP containing extracts as obtained in example I, with or without a concentration step. 15 The recrystallisation inhibition properties of several samples was measured. The AFP juices obtained after extraction and heating in accordance to example I were measured for their recrystallisation properties as above. 20 Non heat treated grass extract from grass harvested in January was obtained from Silsoe (UK). The extract was centrifuged for 1 hour to remove soil and insoluble debris as follows, Centrifuge:Sorvall RC3C,Rotor:H6000A, 25 Temperature:+5°C, Rotor Speed:SOOOrpm(7268g). A sample of the extract was freeze dried to determine its total solids content. This was found to be 11.48 mg/ml. The dried extract was then rehydrated with 30% Sucrose solution 30 to its original total solids concentration. Several solutions were prepared by diluting the extract as necessary with 30% Sucrose solution. Ice crystal recrystallisation inhibition activity was WO 99/37782 PCT/EP98/08553 measured using the assay as described above. The T=0 and T=l hour pictures from, the recrystallisation inhibition assays had their mean ice crystal sizes measured 5 using the Zeiss TGA 10 analyser. The ice-crystal size (length) was determined by drawing around the perimeter of the crystals. The maximum length for each individual ice crystal of a batch of ice cream was imported into a spreadsheet where analysis of the data set was carried out 10 to find the mean, and standard deviation. The results obtained are shown in the table below. 15 These results show the variation in final crystal size and the change in ice crystal size over 1 hour at -6°C for the WO 99/37782 PCT/EP98/08553 various dilutions of grass extract. It can be seen that the solids level in the grass extract can be varied in a wide xange while still good recrystallisation inhibition properties are obtained. Preferably those concentrations 5 are chosen which result in an ice crystal size after 1 hour of 15 micrometer or less. A similar test was done with grass extract which had been subjected to heat treatment (10 minutes at 100 °C). No 10 significant deterioration of recrystallisation inhibition properties was seen. Additionally the grass extracts of example I were tested using the same recrystallisation inhibition test. The 15 following results were obtained: Heat Crystal Size in μm treatment T=0 T=l 20 60 °C 1 hour 9.6 11.1 Boil 10 minutes 9.8 11.3 These results show that even after heating the extract of cold acclimatised grass maintained the ability to inhibit 25 ice crystal growth. WO 99/37782 PCT/EP98/08SS3 Example IV Seed of perennial rye grass (Lolium perenne) was supplied by 5 Barenbrug (UK) Ltd. The seed was planted in 9 inch pots in Levingtons No.2 compost and after germination, which usually occurred between 4-7 days after planting, the plants were grown on in the glass house for a further 7-10 days until they were approximately 15-20cm high. The plants were then 10 transferred to a cold room for cold acclimation. Acclimation was for 30 days at +4°C with 8-16 hours light/dark. Cold acclimated leaves were cut and homogenised in 50mM Tris, lOmM EDTA adjusted to the required pH with 15 concentrated HCl. Homogenisation was for 2x 30s in a Waring blender with a 2.5:1 ratio (w/w) of buffer to leaf. The homogenate was then placed in a boiling water bath for 10 minutes and" collected through four layers of muslin. The 20 collected supernatant was further centrifuged at 15,000 xg in the 8 x 50ml rotor of a Sorvall centrifuge. Ice recrystallisation properties were tested by the method described in example III. 25 Heat stable extract (10-50ml) was concentrated approximately ten-fold in an Amicon concentrator using a PM10 membrane, lml aliquots of concentrate were desalted on a Fast Desalting Column on a FPLC separation system (Pharmacia). 30 The column was run at lml min"1 in 50mM Tris/Cl, lOmM EDTA, pH8.5. Fraction (lml) collection was initiated as soon as the monitored O.D. 280nm started to rise. The RI active WO 99/37782 PCT/EP98/085S3 fractions were pooled, typically in a volume of 3ml. The RI activity was loaded onto a Mono Q (HR5 x 5) column equilibrated in the same Tris, pH8.5 buffer. The pass was 5 collected as a single fraction and the column was immediately eluted with a linear gradient of 0-0.25M NaCl over 25 minutes at 1 ml min-1. The whole activity was routinely found to remain unbound eluting solely in the pass fraction. 10 The pass fraction was readjusted, carefully to pH9.5 using 1 microlitre drops of 4M NaOH and loaded onto the Mono Q column which had been re-equilibrated in Tris buffer pH9.5. The pass was collected as a single fraction and then the 15 column was immediately eluted with a 0-0.25M NaCl linear gradient over 25 minutes. The flow rate was 1ml min-1 and lml fractions were collected for RI assay. The whole activity was found to have bound to the column and no activity was found in the pass fraction. Activity eluted as 20 a single peak between 0.08 and 0.14M NaCl. The active peak fractions from the Mono Q column were pooled, concentrated to 50 microlitre on a PM10 Centricon concentrator and loaded onto a Sephadex 75 column on the 25 Smart system (Pharmacia) . The column was equilibrated in 50mM Tris/Cl pH9.5 buffer and the flow rate was 50 microlitre min-1. Sample collection was delayed for 1.0 microlitre to allow for the void volume of the column and then 50ml fractions were collected. The active fractions 30 were run on SDS PAGE. Samples were run on 10% Nu Page gels from Novex. The samples and gel buffer were prepared as described in the WO 99/37782 PCT7EP98/08553 manufacturers instructions and gels were stained using a Novex silver staining kit. The active fractions contained a single stained protein band with an apparent molecular weight of 29 kDa. 5 . Protein samples were also separated by SDS PAGE followed by electroblotting onto PVDF membrane based on the method of Matsudaira in lOmM GAPS buffer, pH 11.0, 10% methanol. The membrane was wetted in methanol and then equilibrated in 10 Caps buffer for 10 minutes. Blotting was for 16 hours at 20 volts constant voltage. After blotting the proteins were visualised by staining .the membrane with 0.2% coomassie brilliant blue in 50% methanol, 1% acetic acid for 1 minute. The membrane was then destained with 50% methanol until the 15 proteins bands were clearly visible. The membrane was washed in Milli Q water, air dried and stored at -20 0C. The N-terminus of the 29 kDa band was sequenced as follows by conventional methods providing the amino acid sequence 20 of: The 29 kDa protein, believed to be the boiling tolerant RI active was immobilised onto PVDF membrane after separation by SDS PAGE and subjected to protein sequencing of the amino-terminus and" 15 of the first 17 residues were 25 successfully sequenced. A 27 kDa protein isolated form Poa pratensis was also sequenced at the N-terminus (Table 1) and shown to have a similar sequence suggesting that it is part of the same protein family. This implies that there is a single class of AFPs responsible for the boiling tolerant RI 30 activity in Gramineae. Table 1 Alignment of the N-terminal sequences of the 29 kDa boiling WO 99/37782 PCT/EP98/08553 tolerant RI active protein from Lolium perenne and the 27 kDa protein from Poa pratensis Lolium -DEQPNTISGXNNTVRXG Poa -AETPNTISGTNN WO 99/37782 PCT/EP98/085S3 Example V The initial extraction was with a 1:1 mix of phenol and 5 chloroform followed by an extraction with chloroform. The phenol will denature the proteins exposing the hydrophobic amino acid residues allowing the protein to partition preferentially into the organic phase. The more hydrophilic nucleic acids and carbohydrates partition into the aqueous 10 phase. Proteins with a significant degree of glycosylation may also partition into the interface. The chlorofom is present as the protein partitions more efficiently when two different organic solvents are used and the final chloroform extraction removes any remaining traces of phenol. 15 The heat stable extract prepared from, leaves of Lolium perenne plants was concentrated approximately ten fold using an Amicon ultrafiltration chamber with a lO kDalton 20 cut-off membrane. The resulting concentrate (0.05ml) was loaded onto a Superdex 75 PC 3.2/30 gel filtration column running on a Smart microseparation system (Pharmacia) . The column was eluted with 50mM Tris/Cl buffer pH 9.5 at a flow rate of 0.05ml min-1 and 0.05 ml fractions collected. The 25 fractions were assayed for ice recrystallisation inhibition activity and the most active fractions were pooled together. These were then loaded onto a Mono Q PC 1.6/5 colmn, equilibrated in 50mM Tris/Cl buffer pH9.5, also run on the Smart system at a flow rate of 0.1ml min-1. After 30 loading and waning, the column was eluted with a linear gradient of 0 - 0.4 M sodium chloride and 0.1ml fractions collected. The fractions were assayed and the activity eluted as a single peak at approximately 0.1M sodium WO 99/37782 PCT/EP98/08553 chloride. The active fraction was vortexed in an equal volume of phenol:chloroform:isoamyl alcohol (1:1[24:1]) for 1 minute. 5 It was then centrifuged at 13,000 x g for 30 minutes. The aqueous (upper) and organic (lower) phases were collected separately, no interface was obersvable. The two phases were then precipitated by the addition of ten volumes of cold acetone and held at - 20°C for 16 hours. The resulting 10 pellets were resuspended in 50 mM tris/Cl buffer, assayed for RI activity and run on SDS PAGE. Assay of the resuspended fractions showed that the RI activity was found to partition completely into the aqueous 15 phase. The organic phase contained no RI activity even after the fraction had been denatured/rertatured in 6M guanidine hydrochloride. This was an unexpected result as a protein would usually have been expected to partition into the organic phase, or a glycoprotein into the interface. 20 However, analysis by SDS PAGE showed that although the majority of the proteins were in the organic phase a single protein band with an apparent molecular weight of 29 kDa was visible in the active aqueous fraction but absent from the organic phase. The band stained with a different colour 25 from the other proteins and was very diffuse. A similar phenol:chloroform extraction was carried out on the boiling tolerant extract prepared from the cold acclimated leaves of a broad leaved perennial meadow grass 30 (Poa pratensis var Barcelona) and this also demonstrated preferential partitioning.of the RI activity into the aqueous phase and a protein of apparently 27 kDa on SDS PAGE. WO 99/37782 PCT/EP98/08553 Protein sequencing of the N-termini of the proteins confirmed that they were identical to the AFPs described in example IV. 5 Example VI A degenerate oligonucleotide primer (Lol 1) was designed and synthesised from the protein N-terminus sequence (ASP-10 GLU-GLN-PRO-ASN-THR-ILE) , as GAYGARCARCCIAAYACIAT where Y = C+T, R = A+G and I = Inosine. First strand cDNA was prepared from 5μg of 30 day cold acclimated Lolium perenne leaf RNA using Superscript 15 Reverse Transcriptase (Stratgene) and an oligonucleotide primer OG1 (GAGAGAGGATCCTCGAG (T) 15) according to the manufacturers instructions. 1% of the first strand cDNA was used as a template, together with Loll and OG1 primers, in PCR reactions. The reactions were carried out in a thermal 20 cycler using Taq DNA Polymerase (Gibco BRL) for 30 cycles ( lminute at 94°C, 1 minute at. 55°C and 1 minute at 72°C) after an initial denaturation step of 2 minutes at 94°C. A PCR product of ~ 600 bp was amplified and subsequently 25 purified from a 1% agarose gel and cloned into the pTAg vector (R&D systems) according to the manufacturers instructions. The cloned PCR product was sequenced on a Perkin Elmer (Applied Biosystems) automated DNA sequencer using T3 and T7 primers. It contained an open reading frame 30 substantially similar to: GAT GAA CAG CCG AAT ACG ATT TCT GGG AGC AAC AAT ACT GTC AGA TCC GGG AGC AAA AAT GTT CTT GCT GGG AAT GAC AAC ACC GTC ATA WO 99/37782 POVEP98/08553 TCT GGG GAC AAC AAT AGT GTG TCT GGG AGC AAC AAC ACT GTC GTA AGT GGG AAT GAC AAT ACC GTA ACC GGC AGC AAC CAT GTC GTA TCA GGG ACA AAC CAT ATC GTT ACA GAC AAC AAC AAT AAC GTA TCC GGG AAC GAT AAT AAT GTA TCC GGG AGC TTT CAT ACC GTA TCC GGG GGG 5 CAC AAT ACT GTG TCC GGG AGC AAC AAT ACC GTA TCT GGG AGC AAC CAC GTT GTA TCT GGA AGC AAC AAA GTC GTG ACA GAC GCT TAA and the deduced amino acid sequence was substantially similar to: 10 D-E-Q-P-N-T-I-S-G-S-N-N-T-V-R-S-G-S-K-N-V-L-A-G-N-D-N-T-V-I-S-G-p-NrN-S-V-S-G-S-N-N-T-V-V-S-G-M-D-N-T-V-T-G-S-N-H-V-V-S-G-T-N-H-I-V-T-D-N-N-N-N-V-S-G-N-D-N-N-V-S-G-S-F-H-T-V-S-G-G-H-N-T-V-S-G-S-N-N-T-V-S-G-S-N-H-V-V-S-G-S-N-K-V-V-T- 15 D-A The open reading frame codes for a protein of - 12kDa molecular weight, which is considerably less, than the apparent molecular weight on SDS PAGE of 29 kDA. The coding 20 sequence is also observed to contain six recognised glycosylation sites (ASN-X-SER/THR) and a substantial number of SER and THR residues which may also be glycosylated. This evidence suggests that the native protein isolated from Lolium is highly glycosylated. 25 However protein that has been enzymically deglycosylated still retains ice recrystallisation inhibition activity suggesting that the glycosylation is not essential for the protein to be active. WO 99/37782 PCT/EP98/08553 Example VII To prove that the Lolium perenne cDNA described in example VI codes for an AFP, expression of the coding region was 5 carried out. A strain of Pichia pastoris, a methylotrophic yeast, was created containing the Lolium AFP cDNA. The Lolium cDNA was cloned into a pPIC9 vector with an a -factor signal sequence to ensure secretion from the cell 10 and glycosylation. All enzymes were from Boehringer Mannheim and used according to the manufacturers instructons. Construction of expression vectors, transformation and growth of Pichia were all as described in the Invitrogen Pichia Expression Kit (Version B) Manual. 15 The Lolium cDNA was cloned into the pPIC9 vector as a PCR amplification fragment, with compatible restriction ends for ligation into the pPIC9 vector. This was produced using Lolium cDNA as the template and the primers 20 GTATCTCTCGAGAAAAGAGATGAGCAGCCGAACACGATT and TTAATTCGCGGCCGCCTGTAGGAAAAGTATGGTATATC which introduced a Xhol restriction site at the 5' end and a Notl restriction site at the 3' end of the amplification fragment and ensured that the Lolium cDNA was in frame with the 25 secretion signal open reading frame. The reactions were carried out in a thermal cycler using Taq DNA polymerase and Pfu proof reading enzyme (Boehringer Mannheim) for 30 cycles (1 minute at 94°C, 1 minute at 55°C and 1 minute at 72°C) . All subsequent PCR reactions were carried out under 30 the same conditions but withiut Pfu enzyme. The Xhol/Notl cDNA fragment was then cloned into the Xhol/Notl digested pPIC 9 vector and transformed into competent E Coli cells WO 99/37782 PCT/EP98/08553 (strain XLl-blue). After transformation, they were plated onto LB plates with SOμg ml ampicillin and grown at 37°C for 16 hours. Then, 20 ampicillin resistant transformants were picked and analysed for integration of the Lolium cDNA 5 by PCR using the 5' AOXl and the 3' AOX1 primers that had been synthesised as specified in the Invitrogen Kit Manual. Plasmid DNA was isolated from four positive transformants 10 by miniprep and linearised by digestion with Sa11 for transformation into Pichia cells that had been grown and washed as described in the Invitrogen Manual. The linearised DNA digests were electroporated into the Pichia cells using a BioRad GenePulser as recommended and after 15 addition of ice cold 1M sorbitol spread on MD plates and grown at 30°C for 24 hours until colonies were visible. 16 transformants were then picked onto fresh MM and MD plates and transformants that grew normally on the MD plates but more slowly on the MM plates were selected. These 20 transformants were then analysed by PCR using the 5'and 3' AOXl primers and 8 positives were tested for expression. Initially the colonies were innoculated into BMGY medium and grown at 30°C for 24 hours after which the cells were 25 spun down and transferred to BMMY medium to induce expression and returned to 30°C for a further 24 hours. Two more additions of methanol to 0.5% were made at 24 and 4 8 hours to maintain induction. The cells were then removed by centrifugation and an aliquot of the medium adjusted to 30% 30 sucrose and assayed for ice recrystallisation inhibition activity. The medium of all the transformants contained significant RI activity whereas medium produced in the same way from control Pichia without the integrated Lolium cDNA WO 99/37782 PCT/EP98/08553 had no activity. The above example demonstrates that the protein isolated from Lolium perenne and the corresponding cDNA represent an 5 RI active AFP. Example VIII E.coli XL-1 blue was used for all cloning steps; cultures 10 were grown on 2YT medium with selection by Ampicillin or Kanamycin as appropriate. All oligonucleotide primers were synthesisied on a Perkin Elmer 381A DNA Synthesiser, using the phosphoramidite method as recommended by the manufacturers. Nurse culture plates were prepared by 15 plating 2ml Of a cell suspension of Nicotiana bethiama on a petri dish containing 25 ml of MS salts, B5 vitamins (lmg L nicotinic acid, 1 mg L pyridoxine, lOmg L thiamine, 100 mg L inisitol) + 1 mg L 2-4D, 0.2 mg L BAP & 0.8% agar. The cells were swirled to cover the agar and then covered with 20 a sterile filter paper disc. Selection media = MS basal media + 3% sucrose, 0.2 mg L IAA, 1 mg L BAP, 0.9% agar + 500 mg L cefotaxime & 100 mg L kanamycin. 25 The Loll sequence encoding the AFP, and a PRla apoplastic targeting sequence, were PCR amplified with 5 and WO 99/37782 PCT/EP98/08553 3 oligonucleotide primers designed to generate the appropriate restriction sites to allow them to be ligated together at a BamHI site and the annealed product inserted into an NcoI/EcoRI opened pUC intermediate plasmid vector 5 (Messing 1983). The Loll AFP was separately inserted into three pUC vectors behind different promoter sequences (Granule bound starch synthase; cauliflower etched ring virus; double 35S cauliflower mosaic virus). They were then further cloned into a plant transformation binary vector 10 and introduced into tobacco using Agrobacteriim mediated transformation. PCR reaction mixtures contained 5μl of xlO Taq rea ction buffer, lμl of dNTPs, lμl of 5 and 3 primers (50 pmol 15 μl), lμl of template Loll, 0, 5μl of Taq polymerase and 0.05μl of pfu proof reading enzyme. Tubes were overlayed with mineral oil and subjected to 30 cycles of 1 minute at 94°C, 1 minute at 55CC and 1 minute at 72°C after an initial denaturation step of 2 minutes at 94°C. 20 Digestions of PCR amplification products were carried out with the appropriate restriction enzymes in the recommended buffer (Boehringer Mannheim) for 16 hours at 37oC. Digestion mixtures were separated on a 1% agarose gel and 25 the relevant bands excised and purified using the Qiagen WO 99/37782 PCT/EP98/08553 quick DNA gel purification kit following the manufacturers recommendations. Insert and plasmid vector were ligated with T4 ligase and 5 xlO buffer as recommended by Stratgene for 16 hours at 16C. Competent E.coli cells were transformed using 2μl of ligation reaction, plated out and grown at 37oC overnight. Transformants were identified by PCR using specific 5 and 3 primers. Plasmid DNA was then isolated as described in 10 Maniatis Volume 1 and correct assembly confirmed by restriction digest analysis. The HindIII/EcoRI inserts were excised and ligated as before into Hindlll/EcoRI digested general plant 15 transformation vector (GPTV). Competent E.coli were transformed-and transformants identified by PCR; subsequently isolated plasmid DNA was confirmed to be correct by sequencing. 20 The three different GPTV vectors were separately transformed into Agrrobacterium tumafaciens (strain LBA 4404) using the freeze thaw method as described in the Plant Molecular Biology manual PMAN A3\7. 25 Nicotiana tabacum (var Petit Havana) seeds were surface WO 99/37782 PCT/EP98/08553 sterilised for 10 minutes with a solution of 10% sodium hyperchlorite and after rinsing three times with distilled water, were transferred to Murashige. & Skoog basal medium + 3% sucrose +0.9% agar. The seeds were grown for two weeks 5 and then thinned to 2 per vessel after which sterile plantlets wer obtained by taking monthly shoot cuttings into MS basal medium + 3% sucrose + 0.9% agar. Agrobacterium cells containing the appropriate plasmid were cultured overnight.in Lennox broth (5g L-1 NaCl, 10 g IT1 10 yeast extract, 10 g L bacto tryptone and 15g L agar), after which they were recovered by centrifuging for 10 minutes at 3000 x g and resuspended in MS basal medium + 3% sucrose. Tobacco leaf discs cut with a sterile cork borer were infected by incubating for 10 minutes with the 15 Agrobacterium culture after which they were patted dry on sterile filter paper and plated face down on a nurse culture plate of tobacco cells. The infected leaf discs were incubated at 26°C for 2 days 20 in a light intensity of 20001ux and then removed from the nurse culture plates to selection media They were then incubated at 3000 lux , 26C, 16 hours day/ 8 hours dark and transferred every two weeks to fresh media. As new growing shoots appeared at the edge of the disc they were 25 removed to MS basal media + 3% sucrose , 500 mg L WO 99/37782 PCT/EP98/08553 cefotaxime & 100 mg L kanamycin for rooting. After rooting and growing to a size where they had 3-4 leaves a leaf from several lines of each construct plus 5 several untransformed control plants was removed for RI assay. The leaf tissue was ground in a eppendorf tube and the sap released was recovered by centrifugation. The sap was adjusted to 30% sucrose (w/v) prior to assay. 10 Several plant lines from each construct were demonstrated to have significant levels of ice recrystallisation inhibition activity. Extracts from each of the control plants possessed no activity. This clearly demonstrated that the Loll AFP had been transformed into tobacco, a 15 plant that does not have its own AFP, and was successfully expressed as an active protein with no need for cold acclimation. Plants selected to be grown on, were potted into a 50% 20 perlite / 50 % peat mix and re-potted to flowering in a 26C 16hour light / 22*C 8 hour dark cycle in a growth room. Flowers were bagged to ensure self-pollination and seed collected and stored at +4oC. 25 Example IX WO 99/37782 PCT/EP98/08553 To prove that the AFP of the invention does not require glycosylation to be active, the coding region was expressed in a prokaryote system. A strain of Escherichia Coli was created containing the Lolium AFP cDNA. 5 The Lolium cDNA was cloned into a pET32 plasmid from Novagen that contains thioredoxin for expression of the target gene as a fusion protein. All enzymes were from Boehringer Mannheim and used according to the manufacturers 10 instructions. Construction of expression plasraids, transformation and growth of E.Coli were all as described in the Novagen pET system manual and Promega Applications guide. 15 The Lolium cDNA was cloned into the pET-32 plasmid as a PCR amplification fragment, with compatible restriction ends for ligation into the multiple cloning site of the pET-32 plasmid. This was produced using Lolium cDNA as the template and a 5' oligonucleotide primer 20 (TTTGCGCTCGAGTTAAGCGTCTGTCACGACTTTG and 3' oligonucleotide primer (TTTGCGCCATGGATGAACAGCCGAATACGATTTC). This introduced a Ncol restriction site at the 5' end and a Xhol restriction site at the 3' end of the amplification fragment. The reactions were carried out in a thermal 25 -cycler using Taq DNA polymerase for 25 cycles (denaturation at 94°C, annealing from 35°C to 60°C, expression at 72°C) . All subsequent PCR reactions were carried' out under the same conditions. The Ncol/Xhol PCR amplified fragment was then cloned into the Ncol/Xhol digested pET-32 plasmid and 30 transformed into competent non-expression E.Coli cells (strain XLl-Blue). After transformation, they were plated onto LB-ampicillin plates and grown at 37°C for 16 hours. 10 ampicillin resistant transformants were picked and analysed for integration of the Lolium cDNA by PCR using WO 99/37782 PCT/EP98/08553 the pET upstream and downstream primers from Novagen. Plasmid DNA was isolated from 3 positive transformants by miniprep and digested by Xhol and Ncol for transformation 5 into the competent expression E.Coli BL21(DE3) cells as described in the pET system manual. The transformed cells were plated onto LB-Ampicillin medium and incubated at 37°C for 24 hours together with a control made with non transformed BL21(DE3) E.C0Ii cells. 10 Three positive transformant colonies were selected and subcultured in LB-arapicillin media and incubated at 37°C for 1 hour to reached an O.D. (λ=600nm) of 0.6 and then inoculated in a larger medium volume and shaken at 37°C. When the O.D. reached 0.5, the cells were induced with IPTG 15 for protein expression for 3 hours as described in the pET system manual. Expressed proteins were isolated from the E.Coli cells cytoplasm as described in the pET system manual; cells were 20 harvested by centr.ifiugati.on, resuspended in HEPES buffer (25mM HEPES, lOmM MgCl2, lOOmM NaCl, 1mM DTT, pH7.5) and sonicated for 10 seconds. The cytoplasmic protein fraction was centrifuged and the supernatant collected. An aliquot of the supernatant was adjusted to 30% sucrose and assayed 25 for ice recrystallisation inhibition activity as described in example III. The cytoplasmic protein extract demonstrated significant RI activity whereas the cytoplasmic protein extract produced in the same way from control E.Coli cells without the integrated Lolium cDNA had 30 no activity. The fusion protein was purified by metal affinity column and the thioredoxin removed; by digestion with thrombin. The identity of the cleaved AFP was confirmed by potein WO 99/37782 PCT/EP98/08553 sequencing of the N-terminus and this cleaved protein was shown to also have significant ice recrystallisation inhibition activity. 5 The above provides proof that the non-glycosylated Lolium perenne antifreeze protein expressed in E.Coli retained its recrystallisation inhibition activity, both as a fusion product with thioredoxin. and after thrombin, cleavage. WE CLAIM: 1. A method of obtaining an anti-freeze protein (AFP) having the amino acid sequence D-E-Q-P-N-T-I-S-G-S-N-N-T-V-R-S-G-S-K-N-V-L-A-G-N-D-N-T-V-I-S-G-D-N-N-S-V-S-G-S-N-N-T-V-V-S-G-N-D-N-T-V-T-G-S-N-H-V-V-S-G-T-N-H-I-V-T-D-N-N-N-N-V-S-G-N-D-N-N-V-S-G-S-F-H-T-V-S-G-G-H-N-T-V-S-G-S-N-N-T-V-S-G-S-N-H-V-V-S-G-S-N-K-V-V- T-D-A (SEQ ID NO: 1), or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, the method comprising: isolating the AFP from a plant. 2. A method according to Claim 1 wherein the plant is a cold- acclimatised grass. 3. A method according to Claim 1 or 2 wherein the AFP has at least 90% overlap with SEQ ID NO: 1. 4. A method according to Claim 3 wherein the AFP has at least 95% overlap with the SEQ ID NO: 1. 5. A method according to any of Claims 1-4 wherein the plant is selected from a perennial grass such as Lolium perenne, Parapholis strigosa, Nardus stricta, Catapodium loliaceum and Lolium multiflorum, Poa trivialis, Poa pratensis, Holcus lanatus, Bromus sterilis and a cereal crop such as winter rye, winter wheat and winter barley. 6. A method according to any of Claims 1-5 wherein the plant is Lolium perenne, Poa trivialis, Holcus lanatus, or Bromus sterilis, or a combination thereof. 7. A method according to any of Claims 1-6 wherein isolating the AFP comprises the steps of: a) isolating an AFP-containing juice from the plant; b) heat treating the plant or the AFP containing juice to a temperature of at least 60°C; and c) removing the insoluble fraction from the AFP-containing juice, wherein steps a) and b) can be performed in any order or simultaneously. 8. A method according to Claim 7 wherein the step of isolating the AFP-containing juice from the plant comprises forming a slurry from the plant or homogenising the plant. 9. A method according to Claim 8 wherein isolating the AFP-containing juice comprises filtering the juice from the slurry or the homogenate. 10. A method according to Claim 7 wherein the plant or the AFP-containing juice is heated to between 60°C and 110°C. 11. A method according to Claim 9 wherein the plant or the AFP-containing juice is heated to between 80°C and 105°C. 12. A method according to Claim 7 wherein the insoluble fraction is removed from the AFP-containing juice by filtration or precipitation. 13. A method according to any of Claims 7-12 further comprising a subsequent processing step of: d) drying the AFP-containing juice to obtain an AFP-containing powder or paste; or e) concentrating the AFP-containing juice to obtain an AFP-concentrate; or f) separating the AFP from the AFP-containing juice. 14. A method according to Claim 13 wherein separating the AFP from the AFP-containing juice is performed by chromatography. 15. A method of obtaining an AFP having the amino acid sequence of SEQ ID NO; 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, wherein the AFP is produced by a genetically modified organism. 16. A method according to Claim 15 comprising: a) providing a polynucleotide that encodes the AFP, and b) expressing the AFP from the polynucleotide in the organism. 17. A method according to Claim 15 or 16 wherein the AFP has at least 90% overlap with SEQ ID NO: 1. 18. A method according to Claim 17 wherein the AFP has at least 95% overlap with SEQ ID NO: 1. 19. A method according to Claim 15 or 16 wherein the polynucleotide that encodes the AFP has the sequence GAT GAA CAG CCG AAT ACG ATT TCT GGG AGC AAC AAT ACT GTC AGA TCC GGG AGC AAA AAT GTT CTT GCT GGG AAT GAC AAC ACC GTC ATA TCT GGG GAC AAC AAT AGT GTG TCT GGG AGC AAC AAC ACT GTC GTA AGT GGG AAT GAC AAT ACC GTA ACC GGC AGC AAC CAT GTC GTA TCA GGG ACA AAC CAT ATC GTT ACA GAC AAC AAC AAT AAC GTA TCC GGG AAC GAT AAT AAT GTA TCC GGG AGC TTT CAT ACC GTA TCC GGG GGG CAC AAT ACT GTG TCC GGG AGC AAC AAT ACC GTA TCT GGG AGC AAC CAC GTT GTA TCT GGA AGC AAC AAA GTC GTG ACA GAC GCT TAA(SEQ ID N0:2). 20. A method according to any of Claims 15 to 19 further comprising the prior step of introducing the polynucleotide into the organism. 21. A method according to any of Claims 15-20 wherein the organism is a microorganism or a plant. 22. A method according to Claim 21 wherein the microorganism is a yeast. 23. A method according to Claim 22 wherein the yeast is Pichia pastoris. 24. A method according to Claim 22 or 23 wherein the polynucleotide additionally encodes an α -factor signal sequence. 25. A method according to Claim 21 wherein the microorganism is a prokaryote. 26. A method according to Claim 25 wherein the prokaryote is Escherichia coli. 27. A method according to Claim 21 wherem the introduction of the polynucleotide into the plant comprises Agrobacterium mediated transformation. 28. A method according to Claim 21 or 27 wherein the plant is a Nicotania. 29. A method of constructing a nucleic acid vector capable of expressing an AFP having the amino acid sequence of SEQ ID NO: 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, in a suitable host organism, the method comprising: a) providing a nucleic acid vector suitable for the host organism; b) providing a polynucleotide that encodes the AFP; c) optionally, providing a further polynucleotide that promotes expression or secretion of the AFP in the host organism, and d) inserting the polynucleotide that encodes the AFP, and any further polynucleotide, into the nucleic acid vector. 30. A method according to Claim 29 wherein the AFP has at least 90% overlap with SEQ ID NO: 1, 31. A method according-to Claim 30 wherein the AFP has at least 95% overlap with SEQ ID NO: 1. 32. A method according to Claim 29 wherein the polynucleotide that encodes the AFP has the sequence of SEQ ID NO: 2. 41. A method according to Claim 40 wherein the yeast is Pichia pastoris 42. A method according to Claim 40 or 41 wherein the polynucleotide also encodes an a-factor signal sequence. 43. A method according to Claim 39 wherein the host microorganism is aprokaryote. 44. A method according to Claim 43 wherein the prokaryote is Escherichia coli. 45. A method according to Claim 39 wherein the introduction of the polynucleotide into a host plant comprises Agrobacterium mediated transformation. 46. A method according to Claim 39 or 45 wherein the host plant is a Nicotania. 47. A method of making a food product containing an AFP having the amino acid sequence of SEQ ID NO: 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, wherein the food-product is genetically modified to produce the AFP. 48. A method of making a food product containing an AFP having the amino acid sequence of SEQ ID NO: 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified 33. A method according to any of Claims 29-32 wherein the suitable host organism is a yeast and wherein the further polynucleotide encodes an α-factor signal sequence. 34. A method according to any of Claims 29-32 wherein the suitable host organism is a plant and wherein the nucleic acid vector is suitable for Agrobacterium mediated transformation into the plant. 35. A method of obtaining a host organism capable of expressing an AFP having the amino acid sequence of SEQ ID NO: 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, the method comprising: a) providing a polynucleotide that encodes the AFP, and b) introducing the polynucleotide into the host organism. 36. A method according to Claim 35 wherein the AFP has at least 90% overlap with SEQ ID NO: 1. 37. A method according to Claim 36 wherein the AFP has at least 95% overlap with SEQ ID NO: 1. 38. A method according to Claim 35 wherein the polynucleotide that encodes the AFP has the sequence of SEQ ID NO: 2. 39. A method according to any of Claims 35-38 wherein the host organism is a microorganism or a plant. 40. A method according to Claim 39 wherein the host microorganism is a yeast. versions thereof whereby said modification does not materially affect the ice recrystallisation properties, comprising adding the AFP to. the food-product 49. A method of making a polynucleotide that encodes an AFP having the amino acid sequence of SEQ ID NO: I, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, the method comprising synthesising or isolating a nucleic acid sequence that encodes the AFP. Dated this 20th day of Jul y 2000. M K CHAKRABARTI OF H V WILLIAMS & CO Agent for the applicant

Full Text

FORM 2 THE PATENTS ACT,1970
( 39 of 1970 )
COMPLETE SPECIFICATION SECTION 10
TITLE
"A METHOD OF PRODUCING AN ANTIFREEZE PROTEIN"
APPLICANT
HINDUSTAN LEVER LIMITED, a Company incorporated under the Indian Companies Act, 1913 and having its Registered Office at Hindustan Lever House, 165/166 Backbay Reclamation, Mumbai 400 020, Maharashtra, India
The following specification particularly describes the nature of the invention and the manner in which it is to be performed

WO 99/37782

PCT/EP98/08553

"A method of producing an anti freeze protein"
5 Technical Field of the Invention
The invention relates to anti-freeze proteins (AFPs) and frozen food product containing AFPs.
10 Background to the Invention
Anti-freeze proteins (AFPs) have been suggested for improving the freezing tolerance of foodstuffs.
15 For the purpose of the invention, the term AFP has the . meaning as well-known in the art, namely those proteins which exhibit the activity of inhibit the growth of ice crystals. See for example US 5/118,792.
20 WO 90/13571 discloses antifreeze peptides produced
chemically or by recombinant DNA techniques. The AFPs can suitably be used in food-products. Example 3B shows modified ice crystal shapes if a water-ice mixture is frozen into a film in combination with 0.01 wt% of AFP.
25
WO 92/22581 discloses AFPs from plants which can be used for controlling ice crystal shape in ice-cream. This document also describes a process for extracting a polypeptide composition from extracellular spaces of plants
30 by infiltrating leaves with an extraction medium without rupturing the plants.
WO 94/03617 discloses the production of AFPs from yeast and their possible use in ice-cream. WO 96/11586 describes fish

WO 99/37782

PCT/EP98/08S53

AFPs produced by microbes.
Several literature places also mention the isolation and/or use of plant proteins for cryoprotection. Cryoprotective 5 proteins have a function in the protection of plant membranes against frost damage. These proteins, however, do not possess recrystallisation inhibition properties and are, therefore, not embraced within the terms AFPs.
10 Hincha in Journal of Plant Physiology, 1992, 140, 236-240 describes the isolation of cryoprotective proteins from cabbage. Volger in Biochimica et Biophysica Acta, 412 (1975), 335-349 describes the isolation of cryoprotective leaf proteins from spinach. Boothe in Plant Physiol (1995),
15 108: 759-803 describes the isolation of proteins from Brassica napus. Again, these proteins are believed to be cryoprotective proteins rather than AFPs. Neven in Plant Molecular Biology 21: 291-305, 1993 describes the DNA characterisation of a spinach cryoprotective protein.
20 Salzman in Abstracts and Reviews of the 18th Annual Meeting" of the ASEV/Eastern Section in Am. J. Enol. Vitic, Vol. 44, No. 4, 1993 describes the presence of boiling-stable polypeptides in buds of Vitis. Although the proteins are analogous to fish antifreeze peptides, they are
25 cryoprotective proteins and not AFPs. Lin in Biochemical and Biophysical Research Communication, Vol. 183, No. 3, 1992, pages 1103-1108 and in Lin, Plant Physiology (1992) 99, 519-525 describes the 15 kDa cryoprotective polypeptide from Arabidopsis Hakaira, Houde in The Plant Journal (1995)
30 8(4), 583-593 mentions cryoprotective proteins from wheat.
Up till now, however the use of AFPs has not been applied to commercially available food products. One reason for

WO 99/37782

PCT/EP98/08553

this are the high costs and complicated process for obtaining AFPs. Another reason is that the AFPs which until now have been "suggested for use in frozen food products cannot be incorporated in the standard formulation mix, 5 because they tend to destabilise during processing especially during the pasteurisation step. This destabilisation is believed to be caused by the denaturation of the AFPs; this is a well-known effect commonly observed for peptides and proteins. 10
In our non pre-published patent application: PCT/EP97/03634 it has been described that AFPs can be isolated from natural sources such as cold-acclimatised grass by means of Via new relatively simple process. This process leads for the 15 first time to the identification of AFPs which can
conveniently be incorporated in a mix for the preparation of frozen products before the pasteurisation thereof.
This process for the recovery of AFPs from grass involves 20 the steps of
a) isolating a AFP containing juice from the grass;
b) heat treating the grass or the AFP containing juice to a temperature of at least 60°C;
c) removing the insoluble fraction.
25
Step c of the above process will usually take place after steps a and b. Step a and b can be done in any desired order, for example step a followed by step b (in that case the AFP rich juice will be heated) or step b followed by 30 step a (in that case the natural source will be heated) or step a and b simultaneously.
This process has a number of advantages. Firstly by using the process it is no longer necessary to avoid rupturing of

WO 99/37782

PCTYEP98/08553

10
15
the grass such as required in the processes according to WO 92/22581. This immediately significantly increases the commercial applicability of the process, for example as compared to WO .92/22581, because high investment costs for specific processing are no longer necessary. Also by using the high temperatures it seems possible to extract from a large group of peptides present in the grass a very active AFP which is very active w.r.t. ice-recrystallisation inhibition properties. Thirdly, contrary to expectations, the use of high temperatures does not denature all the proteinaceous material, but does only seem to denature some of; the proteins, while the remaining grass AFP have an increased temperature stability. This renders it possible to include the isolated AFPs in compositions which need to be subjected to higher temperatures e.g. a pasteurisation step. This is especially surprising, because for example the AFPs from WO 92/22581 appear not stable under heating conditions.
20 The process as described above includes in step b the .
heating of the grass or the AFP rich juice to a temperature of more than 60°C. Preferably the temperature is from 60 to 110 °C, most preferably from 80 to 105oc. The heating step can take place after the isolation of the protein rich
25 juice (step a) or before the isolation of the protein rich juice. Any suitable way to heat the juice can be used, for example conventional or microwave heating, heating optionally with an added extraction medium, steaming etc.
30 If an extraction medium is used, preferably it is used in small volumes to avoid unnecessary dilution of the AFP fraction. Any suitable extraction medium can be used, although the use of water is especially preferred. If desired, additives may be added to the water prior to using

WO 99/37782

PCT7EP98/08553

it as an extraction medium. Most preferred, however water substantially free of additives is used.
Applicants have also found that by the above process a-very 5 active AFP derived from grass can be derived. For the purpose of the invention the term grass encompasses members of the Graroineae family including for example perennial grass such as Lolium perenne, Parapholis strigosa, Nardus stricta, Catapodium loliaceum and Lolium multiflorum, Poa 10 trivialis, Poa pratensis and cereal crops such as winter rye, winter wheat and winter barley. Applicants have determined the amino acid sequence of this AFP.
Surprisingly it has been found that very active AFPs which 15 can be derived from plants are characterised by a high level of the amino acids: Serine (S), Threonine (T) and Asparagine (N)• In particular applicants have found that preferred AFPs of the invention are characterised in that at least 40% of the amino acids in the protein are selected 20 from S, T and N- Preferably the AFPs are derived from grasses, especially the Gramineae family.
The preferred molecular weight of AFPs of the invention is form 8 to 16 kDa, more preferred 10-14 kDa, where this 25 molecular weight is determined from the gene sequence or by mass spectrometry of the unmodified form e.g. in unglycosylated form.
A second aspect of the invention relates to an AFP which 30 can be derived from grass, said AFP having an amino acid sequence from the N-terminus of:

WO 99/37782

PCT/EP98/085S3

D-E-Q-P-N-T-I-S-G-S-N-N-T-V-R-S-G-S-K-N-V-L-A-G-N-D-N-T-V-
I-S-G-D-N-N-S-V-S-G-S-N-N-T-V-V-S-G-N-D-N-T-V-T-G-S-N-H-V-5
V-S-G-T-N-H-I-V-T-D-N-N-N-N-V-S-G-N-D-N-N-V-S-G-S-F-H-T-V-
S-G-G-H-N-T-V-S-G-S-N-N-T-V-S-G-S-N-H-V-V-S-G-S-N-K-V-V-T-
10 D-A
Also embraced in the scope of our invention are proteins having a sequence which has a high degree of similarity with the above sequence. For the purpose of the invention
15 all RI active proteins having an amino acid sequence of at least 80% overlap with the above sequence are also embraced in the scope of the invention. More preferred is an overlap of at least 90%, most preferred more than 95%, e.g. those amino acid sequences which differ none or only one or two
20 amino acids with the above sequence. Also isoforms of the above protein are embraced within the invention.
Also embraced within the scope of the present invention are modified versions of the above described proteins whereby 25 said modification does not materially affect the ice recrystallisation inhibition properties, such as glycosylated versions thereof.
The AFP rich juice can be. separated from the grass by any 30 convenient process for example pressing, filtering,
homogenising, extraction etc. Preferably the grass is made into small pieces or into a slurry before the protein rich fraction is collected, for example by filtering. This maceration can be done by any suitable method, for example

WO 99/37782

PCT/EP98/08553

in a blender. It will be well within the ability of the skilled person to divide the material into such a form that collection of the protein rich juice can readily take place.. 5
After collecting and heating (in the desired order), the protein fraction the resulting AFP containing sample can then be treated by any convenient process in order to remove the insoluble fraction and retain the AFP rich
10 liquid fraction. The insoluble fraction can be removed e.g. by filtering, precipitation etc. The AFP rich liquid can then advantageously be further processed to concentrate or isolate the AFPs to bring them in a form suitable for further use. Examples of suitable processes are drying to
15 obtain a powder or paste, further concentration to obtain an AFP concentrate, chromatography to separate the AFPs from the extraction medium etc. Again it will be well within the ability of the skilled person to determine the suitable means and conditions for appropriate isolation.
20
Applicants have also determined the nucleic acid sequence that encodes the above described AFP. Accordingly a second aspect of the invention relates to a nucleic acid sequence capable of encoding for the AFPs of the invention.
25 Preferably said nucleic acid has the sequence of:

WO 99/37782

PCT/EP98/08SS3

GAT GAA CAG CCG AAT ACG ATT TCT GGG AGC AAC AAT ACT GTC AGA TCC GGG AGC AAA AAT GTT CTT GCT GGG AAT GAC AAC ACC GTC ATA 5 TCT GGG GAC AAC AAT AGT GTG TCT GGG AGC AAC AAC ACT GTC GTA AGT GGG AAT GAC AAT ACC GTA ACC GGC AGC AAC CAT GTC GTA TCA GGG ACA AAC CAT ATC GTT ACA GAC AAC AAC AAT AAC GTA TCC GGG AAC GAT AAT AAT GTA TCC GGG AGC TTT CAT ACC GTA TCC GGG GGG CAC AAT ACT GTG TCC GGG AGC AAC AAT ACC GTA TCT GGG AGC AAC 10 CAC GTT GTA TCT GGA AGC AAC AAA GTC GTG ACA GAC GCT TAA
Also embraced within the scope of the present invention are alleles or other nucleic acid sequences which are capable to encode the above described AFPs, for example those 15 nucleic acid sequences wherein wrt the above sequence one or more codons have been replaced by their synonyms (i.e. codons encoding for the same amino acid).
Vectors containing a nucleic acid sequence capable of 20 encoding the AFP of the invention are also embraced within the scope of the invention.
Based on the above information it is also possible to genetically modify other natural sources such that 25 they produce the advantageous AFP as identified here-above.
Applicants also have found that AFPs of the above sequence have improved ice-recrystallidation inhibition properties. A suitable test for determining the ice recrystallisation 30 inhibition properties is described in the examples and involves the quick freezing to -40oc followed by storage

WO 99/37782

PCT/EP98/08553

for one hour at -60c. Preferably AFPs which are subject to this test after heat-treatment result in an ice crystal particle size which is less than 5 μm larger than the ice crystal size of a sample with the same AFP which was not 5 heat-treated, preferably the difference is less than 3 urn, most preferred less than 1 μm.
Preferably those AFPs are chosen which have significant ice-recrystallisation inhibition properties. A suitable
10 test for determining the recrystallisation inhibition
properties is indicated in the examples. Preferably AFPs in accordance to the invention provide a ice particle size following an ice recrystallisation inhibition assay -as described in the examples- of 15 μm or less, more preferred
15 from 5 to 15 μm.
The AFP of the invention can conveniently be used in food products, preferably in food products which are frozen or intended to be frozen. Especially preferred is the use of 20 AFPs in products which are heated e.g. by pasteurisation, blanching or sterilisation prior to freezing. Especially preferred is the use in frozen confectionery products.
Examples of such food products are: frozen confectionery 25 mixes such as ice-cream mixes and water-ice mixes which are intended to be pasteurised prior to freezing. Such mixes are usually stored at ambient temperature. Suitable product forms are for example: a powder mix, which is packed for example in a bag or in sachets. Said mix being capable of 30 forming the basis of the frozen food product e.g. after addition of water and optionally other ingredients and -optional- aeration.

WO 99/37782

PCT/EP98/085S3

Another example of a suitable mix could be a liquid mix (optionally aerated) which, if necessary after addition of further components and optional further aeration can be frozen. 5 The clear advantage of the above mentioned mixes is that the presence of the AFP ingredient makes that the mixes can be frozen under quiescent conditions, for example in a shop or home freezer without the formation of unacceptable ice 10 crystal shapes and hence with a texture different to products normally obtained via quiescent freezing.
Very conveniently these mixes are packed in closed containers (e.g. cartons, bags, boxes, plastic containers 15 etc) . For single portions the pack size will generally be from 10 to 1000 g. For multiple portions pack sizes of up to 500 kg may be suitable. Generally the pack size will be from 10 g to 5000 gl
20 As indicated above the preferred products wherein the AFPs are used are frozen confectionery product such as ice-cream or water-ice. Preferably the level of AFPs is from 0.00001 to 0.5 wt% based on the final product. If dry-mixes or concentrates are used, the concentration may be higher in
25 order to ensure that the level in the final frozen product is within the above ranges.
For the purpose of the invention the term frozen confectionery product includes milk containing frozen 30 confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees. For some applications the use in fermented food products is less preferred.

WO 99/37782 PCT/EP98/08553
Preferably a the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 4 wt%, for example more than 30 wt%, more preferred from 40 to 70wt%.
5 Frozen confectionery products according to the invention can be produced by any method suitable for the production of frozen confectionery. Especially preferably however all the ingredients of the formulation are fully mixed before pasteurisation and before the freezing process starts. The 10 freezing process may advantageously involve a hardening
step, for example to a temperature of -30 Celsius or lower.

WO 99/37782

Example I
Isolation of AFPs by first heating grass, followed by isolating the AFP rich juice and isolation of the AFP.
Mixed grass tissue (Poa Trivialis, Lolium Perenne, Holcus Lanatus, Bromus Sterilis) was cut in January (mean temperature in that month was 3.5 °C ensuring the appropriate cold acclimatization of the plants). The grass 10 tissue was rapidly transported into the laboratory for
further handling and washed thoroughly with water to remove dirt.
500 g of grass clippings was placed in a 650 Watt microwave 15 oven and heated at full power for 5 minutes, whereby the temperature was raised to 85 to lOOoC. The grass clippings were then cooled to ambient temperature.
Alternatively the grass clippings are mixed with 500 g 20 boiling water and the mixture is re-heated to 100 °C
followed by boiling for 10 minutes under stirring and then allowed to cool to 60 °C.
After the heating step the AFP rich juice was separated 25 from the clippings by filtering. The mass was stirred continuously for 5 minutes in the presence of an equal volume of water and then squeezed through 3 layers of muslin.
30 The supernatant can be freeze dried to remove the water followed by storage. Alternatively the supernatant can be frozen for storage.

WO 99/37782 PCT/EP98/08553
Example II
A liquid premix for the preparation of ice-cream was
prepared by mixing: 5
Ingredient % by weight
Skimmed milk powder 10.00
sucrose ,13.00
maltodextrine (MD40) 4.00
10 Locust bean gum 0.14
butter oil 8.00
monoglyceride (palmitate) 0.30
vanillin 0.01
AFP (of example I*) 0.01 or none (control)
15 water balance
*Note: AFP is added as concentrated AFP solution in some of the water, percentage refers to amount of AFP.
20
The ingredients were mixed at ambient temperature followed by pasteurisation for 60 seconds at 89°C. The mix was aseptically filled into packs of 500 ml, sealed and stored at ambient temperatures.
25
The mix can be used for the preparation of ice-cream by whipping it with a conventional house-hold mixer to an overrun of about 70 % followed by freezing under quiescent conditions in a house-hold freezer.
30
After two months storage the composition according to the invention had a markedly better texture than the control sample.

WO 99/37782

PCT/EP98/08553

Example III
The ice recrystallisation inhibition properties of the AFPs can determined as follows: 5 A sample of an AFP containing product was adjusted to a sucrose level of 30 wt% (If the starting level of the sample was more than 30% this was done by dilution, if the starting level was lower sucrose was added to the 30% 10 level).
A 3 μL drop of the sample was placed on a 22 mm coverslip. A 16 mm diameter cover-slip was then placed on top and a 200 g weight was placed on the sample to ensure a uniform 15 slide thickness. The edges of the coverslip were sealed with clear nail varnish.
The slide was placed on a Linkham THM 600 temperature controlled microscope stage, the stage was cooled rapidly 20 (50 oC per minute) to -40°C to produce a large population of small crystals. The stage temperature was then raised rapidly (50oc per minute) to -6 °C and held at this temperature.
25 The ice-phase was observed at -6 oC using a Leica Aristoplan microscope. Polarised light conditions in conjunction with a lambda plate were used to enhance the contrast of the ice crystals. The state of the ice phase (size of ice crystals) was recorded by 35 mm
30 photomicrography at T=0 and T=l hour.
Generally this test can be applied to any suitable composition comprising AFP and water. Generally the level of AFP in such a test composition is not very critical and

WO 99/37782

PCT/EP98/08553

can for example be from 0.0001 to 0.5 wt%, more preferred 0.0005 to 0.1 wt%, most preferred 0.001 to 0.05 wt%, for example 0.01 wt%
5 Any suitable composition comprising AFP and water can be used to carry out the test. Generally, however, it will not be necessary to obtain the AFP in purified form. For practical applications normally it would suffice to prepare a liquid extract or juice of natural material, wherein this 10 extract or juice can then be tested.
This method can be applied for example to the AFP containing extracts as obtained in example I, with or without a concentration step.
15
The recrystallisation inhibition properties of several samples was measured. The AFP juices obtained after extraction and heating in accordance to example I were measured for their recrystallisation properties as above.
20
Non heat treated grass extract from grass harvested in January was obtained from Silsoe (UK). The extract was centrifuged for 1 hour to remove soil and insoluble debris as follows, Centrifuge:Sorvall RC3C,Rotor:H6000A,
25 Temperature:+5°C, Rotor Speed:SOOOrpm(7268g).
A sample of the extract was freeze dried to determine its total solids content. This was found to be 11.48 mg/ml. The dried extract was then rehydrated with 30% Sucrose solution 30 to its original total solids concentration. Several solutions were prepared by diluting the extract as necessary with 30% Sucrose solution.
Ice crystal recrystallisation inhibition activity was

WO 99/37782

PCT/EP98/08553

measured using the assay as described above.
The T=0 and T=l hour pictures from, the recrystallisation inhibition assays had their mean ice crystal sizes measured 5 using the Zeiss TGA 10 analyser. The ice-crystal size
(length) was determined by drawing around the perimeter of the crystals. The maximum length for each individual ice crystal of a batch of ice cream was imported into a spreadsheet where analysis of the data set was carried out 10 to find the mean, and standard deviation.
The results obtained are shown in the table below.

15 These results show the variation in final crystal size and the change in ice crystal size over 1 hour at -6°C for the

WO 99/37782 PCT/EP98/08553
various dilutions of grass extract. It can be seen that the solids level in the grass extract can be varied in a wide xange while still good recrystallisation inhibition properties are obtained. Preferably those concentrations 5 are chosen which result in an ice crystal size after 1 hour of 15 micrometer or less.
A similar test was done with grass extract which had been subjected to heat treatment (10 minutes at 100 °C). No 10 significant deterioration of recrystallisation inhibition properties was seen.
Additionally the grass extracts of example I were tested using the same recrystallisation inhibition test. The 15 following results were obtained:
Heat Crystal Size in μm
treatment T=0 T=l
20 60 °C 1 hour 9.6 11.1
Boil 10 minutes 9.8 11.3
These results show that even after heating the extract of cold acclimatised grass maintained the ability to inhibit 25 ice crystal growth.

WO 99/37782

PCT/EP98/08SS3

Example IV
Seed of perennial rye grass (Lolium perenne) was supplied by 5 Barenbrug (UK) Ltd. The seed was planted in 9 inch pots in Levingtons No.2 compost and after germination, which usually occurred between 4-7 days after planting, the plants were grown on in the glass house for a further 7-10 days until they were approximately 15-20cm high. The plants were then 10 transferred to a cold room for cold acclimation. Acclimation was for 30 days at +4°C with 8-16 hours light/dark.
Cold acclimated leaves were cut and homogenised in 50mM Tris, lOmM EDTA adjusted to the required pH with 15 concentrated HCl. Homogenisation was for 2x 30s in a Waring blender with a 2.5:1 ratio (w/w) of buffer to leaf.
The homogenate was then placed in a boiling water bath for 10 minutes and" collected through four layers of muslin. The 20 collected supernatant was further centrifuged at 15,000 xg in the 8 x 50ml rotor of a Sorvall centrifuge.
Ice recrystallisation properties were tested by the method described in example III.
25
Heat stable extract (10-50ml) was concentrated approximately ten-fold in an Amicon concentrator using a PM10 membrane, lml aliquots of concentrate were desalted on a Fast Desalting Column on a FPLC separation system (Pharmacia).
30 The column was run at lml min"1 in 50mM Tris/Cl, lOmM EDTA, pH8.5. Fraction (lml) collection was initiated as soon as the monitored O.D. 280nm started to rise. The RI active

WO 99/37782

PCT/EP98/085S3

fractions were pooled, typically in a volume of 3ml.
The RI activity was loaded onto a Mono Q (HR5 x 5) column equilibrated in the same Tris, pH8.5 buffer. The pass was 5 collected as a single fraction and the column was
immediately eluted with a linear gradient of 0-0.25M NaCl over 25 minutes at 1 ml min-1. The whole activity was routinely found to remain unbound eluting solely in the pass fraction.
10
The pass fraction was readjusted, carefully to pH9.5 using 1 microlitre drops of 4M NaOH and loaded onto the Mono Q column which had been re-equilibrated in Tris buffer pH9.5. The pass was collected as a single fraction and then the
15 column was immediately eluted with a 0-0.25M NaCl linear gradient over 25 minutes. The flow rate was 1ml min-1 and lml fractions were collected for RI assay. The whole activity was found to have bound to the column and no activity was found in the pass fraction. Activity eluted as
20 a single peak between 0.08 and 0.14M NaCl.
The active peak fractions from the Mono Q column were pooled, concentrated to 50 microlitre on a PM10 Centricon concentrator and loaded onto a Sephadex 75 column on the
25 Smart system (Pharmacia) . The column was equilibrated in 50mM Tris/Cl pH9.5 buffer and the flow rate was 50 microlitre min-1. Sample collection was delayed for 1.0 microlitre to allow for the void volume of the column and then 50ml fractions were collected. The active fractions
30 were run on SDS PAGE.
Samples were run on 10% Nu Page gels from Novex. The samples and gel buffer were prepared as described in the

WO 99/37782 PCT7EP98/08553

manufacturers instructions and gels were stained using a

Novex silver staining kit. The active fractions contained a

single stained protein band with an apparent molecular

weight of 29 kDa.
5 .
Protein samples were also separated by SDS PAGE followed by electroblotting onto PVDF membrane based on the method of Matsudaira in lOmM GAPS buffer, pH 11.0, 10% methanol. The membrane was wetted in methanol and then equilibrated in
10 Caps buffer for 10 minutes. Blotting was for 16 hours at 20 volts constant voltage. After blotting the proteins were visualised by staining .the membrane with 0.2% coomassie brilliant blue in 50% methanol, 1% acetic acid for 1 minute. The membrane was then destained with 50% methanol until the
15 proteins bands were clearly visible. The membrane was washed in Milli Q water, air dried and stored at -20 0C.
The N-terminus of the 29 kDa band was sequenced as follows by conventional methods providing the amino acid sequence 20 of:
The 29 kDa protein, believed to be the boiling tolerant RI active was immobilised onto PVDF membrane after separation by SDS PAGE and subjected to protein sequencing of the amino-terminus and" 15 of the first 17 residues were
25 successfully sequenced. A 27 kDa protein isolated form Poa pratensis was also sequenced at the N-terminus (Table 1) and shown to have a similar sequence suggesting that it is part of the same protein family. This implies that there is a single class of AFPs responsible for the boiling tolerant RI
30 activity in Gramineae.
Table 1
Alignment of the N-terminal sequences of the 29 kDa boiling

WO 99/37782

PCT/EP98/08553

tolerant RI active protein from Lolium perenne and the 27 kDa protein from Poa pratensis
Lolium -DEQPNTISGXNNTVRXG
Poa -AETPNTISGTNN

WO 99/37782

PCT/EP98/085S3
Example V
The initial extraction was with a 1:1 mix of phenol and 5 chloroform followed by an extraction with chloroform. The phenol will denature the proteins exposing the hydrophobic amino acid residues allowing the protein to partition preferentially into the organic phase. The more hydrophilic nucleic acids and carbohydrates partition into the aqueous
10 phase. Proteins with a significant degree of glycosylation may also partition into the interface. The chlorofom is present as the protein partitions more efficiently when two different organic solvents are used and the final chloroform extraction removes any remaining traces of
phenol.
15 The heat stable extract prepared from, leaves of Lolium perenne plants was concentrated approximately ten fold using an Amicon ultrafiltration chamber with a lO kDalton
20 cut-off membrane. The resulting concentrate (0.05ml) was loaded onto a Superdex 75 PC 3.2/30 gel filtration column running on a Smart microseparation system (Pharmacia) . The column was eluted with 50mM Tris/Cl buffer pH 9.5 at a flow rate of 0.05ml min-1 and 0.05 ml fractions collected. The
25 fractions were assayed for ice recrystallisation inhibition activity and the most active fractions were pooled together. These were then loaded onto a Mono Q PC 1.6/5 colmn, equilibrated in 50mM Tris/Cl buffer pH9.5, also run on the Smart system at a flow rate of 0.1ml min-1. After
30 loading and waning, the column was eluted with a linear gradient of 0 - 0.4 M sodium chloride and 0.1ml fractions collected. The fractions were assayed and the activity eluted as a single peak at approximately 0.1M sodium

WO 99/37782 PCT/EP98/08553
chloride.
The active fraction was vortexed in an equal volume of phenol:chloroform:isoamyl alcohol (1:1[24:1]) for 1 minute. 5 It was then centrifuged at 13,000 x g for 30 minutes. The aqueous (upper) and organic (lower) phases were collected separately, no interface was obersvable. The two phases were then precipitated by the addition of ten volumes of cold acetone and held at - 20°C for 16 hours. The resulting 10 pellets were resuspended in 50 mM tris/Cl buffer, assayed for RI activity and run on SDS PAGE.
Assay of the resuspended fractions showed that the RI activity was found to partition completely into the aqueous
15 phase. The organic phase contained no RI activity even after the fraction had been denatured/rertatured in 6M guanidine hydrochloride. This was an unexpected result as a protein would usually have been expected to partition into the organic phase, or a glycoprotein into the interface.
20 However, analysis by SDS PAGE showed that although the
majority of the proteins were in the organic phase a single protein band with an apparent molecular weight of 29 kDa was visible in the active aqueous fraction but absent from the organic phase. The band stained with a different colour
25 from the other proteins and was very diffuse.
A similar phenol:chloroform extraction was carried out on the boiling tolerant extract prepared from the cold acclimated leaves of a broad leaved perennial meadow grass 30 (Poa pratensis var Barcelona) and this also demonstrated preferential partitioning.of the RI activity into the aqueous phase and a protein of apparently 27 kDa on SDS PAGE.

WO 99/37782

PCT/EP98/08553

Protein sequencing of the N-termini of the proteins confirmed that they were identical to the AFPs described in example IV. 5
Example VI
A degenerate oligonucleotide primer (Lol 1) was designed and synthesised from the protein N-terminus sequence (ASP-10 GLU-GLN-PRO-ASN-THR-ILE) , as GAYGARCARCCIAAYACIAT where Y = C+T, R = A+G and I = Inosine.
First strand cDNA was prepared from 5μg of 30 day cold acclimated Lolium perenne leaf RNA using Superscript
15 Reverse Transcriptase (Stratgene) and an oligonucleotide primer OG1 (GAGAGAGGATCCTCGAG (T) 15) according to the manufacturers instructions. 1% of the first strand cDNA was used as a template, together with Loll and OG1 primers, in PCR reactions. The reactions were carried out in a thermal
20 cycler using Taq DNA Polymerase (Gibco BRL) for 30 cycles ( lminute at 94°C, 1 minute at. 55°C and 1 minute at 72°C) after an initial denaturation step of 2 minutes at 94°C.
A PCR product of ~ 600 bp was amplified and subsequently 25 purified from a 1% agarose gel and cloned into the pTAg vector (R&D systems) according to the manufacturers instructions. The cloned PCR product was sequenced on a Perkin Elmer (Applied Biosystems) automated DNA sequencer using T3 and T7 primers. It contained an open reading frame 30 substantially similar to:
GAT GAA CAG CCG AAT ACG ATT TCT GGG AGC AAC AAT ACT GTC AGA TCC GGG AGC AAA AAT GTT CTT GCT GGG AAT GAC AAC ACC GTC ATA

WO 99/37782 POVEP98/08553
TCT GGG GAC AAC AAT AGT GTG TCT GGG AGC AAC AAC ACT GTC GTA AGT GGG AAT GAC AAT ACC GTA ACC GGC AGC AAC CAT GTC GTA TCA GGG ACA AAC CAT ATC GTT ACA GAC AAC AAC AAT AAC GTA TCC GGG AAC GAT AAT AAT GTA TCC GGG AGC TTT CAT ACC GTA TCC GGG GGG 5 CAC AAT ACT GTG TCC GGG AGC AAC AAT ACC GTA TCT GGG AGC AAC CAC GTT GTA TCT GGA AGC AAC AAA GTC GTG ACA GAC GCT TAA
and the deduced amino acid sequence was substantially similar to:
10
D-E-Q-P-N-T-I-S-G-S-N-N-T-V-R-S-G-S-K-N-V-L-A-G-N-D-N-T-V-I-S-G-p-NrN-S-V-S-G-S-N-N-T-V-V-S-G-M-D-N-T-V-T-G-S-N-H-V-V-S-G-T-N-H-I-V-T-D-N-N-N-N-V-S-G-N-D-N-N-V-S-G-S-F-H-T-V-S-G-G-H-N-T-V-S-G-S-N-N-T-V-S-G-S-N-H-V-V-S-G-S-N-K-V-V-T-
15 D-A
The open reading frame codes for a protein of - 12kDa molecular weight, which is considerably less, than the apparent molecular weight on SDS PAGE of 29 kDA. The coding
20 sequence is also observed to contain six recognised glycosylation sites (ASN-X-SER/THR) and a substantial number of SER and THR residues which may also be glycosylated. This evidence suggests that the native protein isolated from Lolium is highly glycosylated.
25 However protein that has been enzymically deglycosylated still retains ice recrystallisation inhibition activity suggesting that the glycosylation is not essential for the protein to be active.

WO 99/37782

PCT/EP98/08553

Example VII
To prove that the Lolium perenne cDNA described in example VI codes for an AFP, expression of the coding region was 5 carried out. A strain of Pichia pastoris, a methylotrophic yeast, was created containing the Lolium AFP cDNA.
The Lolium cDNA was cloned into a pPIC9 vector with an a -factor signal sequence to ensure secretion from the cell 10 and glycosylation. All enzymes were from Boehringer Mannheim and used according to the manufacturers instructons. Construction of expression vectors, transformation and growth of Pichia were all as described in the Invitrogen Pichia Expression Kit (Version B) Manual.
15
The Lolium cDNA was cloned into the pPIC9 vector as a PCR amplification fragment, with compatible restriction ends for ligation into the pPIC9 vector. This was produced using Lolium cDNA as the template and the primers 20 GTATCTCTCGAGAAAAGAGATGAGCAGCCGAACACGATT and
TTAATTCGCGGCCGCCTGTAGGAAAAGTATGGTATATC which introduced a
Xhol restriction site at the 5' end and a Notl restriction site at the 3' end of the amplification fragment and ensured that the Lolium cDNA was in frame with the
25 secretion signal open reading frame. The reactions were carried out in a thermal cycler using Taq DNA polymerase and Pfu proof reading enzyme (Boehringer Mannheim) for 30 cycles (1 minute at 94°C, 1 minute at 55°C and 1 minute at 72°C) . All subsequent PCR reactions were carried out under
30 the same conditions but withiut Pfu enzyme. The Xhol/Notl cDNA fragment was then cloned into the Xhol/Notl digested pPIC 9 vector and transformed into competent E Coli cells

WO 99/37782 PCT/EP98/08553
(strain XLl-blue). After transformation, they were plated onto LB plates with SOμg ml ampicillin and grown at 37°C for 16 hours. Then, 20 ampicillin resistant transformants were picked and analysed for integration of the Lolium cDNA 5 by PCR using the 5' AOXl and the 3' AOX1 primers that had been synthesised as specified in the Invitrogen Kit Manual.
Plasmid DNA was isolated from four positive transformants 10 by miniprep and linearised by digestion with Sa11 for transformation into Pichia cells that had been grown and washed as described in the Invitrogen Manual. The linearised DNA digests were electroporated into the Pichia cells using a BioRad GenePulser as recommended and after 15 addition of ice cold 1M sorbitol spread on MD plates and grown at 30°C for 24 hours until colonies were visible. 16 transformants were then picked onto fresh MM and MD plates and transformants that grew normally on the MD plates but more slowly on the MM plates were selected. These 20 transformants were then analysed by PCR using the 5'and 3' AOXl primers and 8 positives were tested for expression.
Initially the colonies were innoculated into BMGY medium and grown at 30°C for 24 hours after which the cells were
25 spun down and transferred to BMMY medium to induce
expression and returned to 30°C for a further 24 hours. Two more additions of methanol to 0.5% were made at 24 and 4 8 hours to maintain induction. The cells were then removed by centrifugation and an aliquot of the medium adjusted to 30%
30 sucrose and assayed for ice recrystallisation inhibition activity. The medium of all the transformants contained significant RI activity whereas medium produced in the same way from control Pichia without the integrated Lolium cDNA

WO 99/37782

PCT/EP98/08553

had no activity.
The above example demonstrates that the protein isolated from Lolium perenne and the corresponding cDNA represent an 5 RI active AFP.
Example VIII
E.coli XL-1 blue was used for all cloning steps; cultures 10 were grown on 2YT medium with selection by Ampicillin or Kanamycin as appropriate. All oligonucleotide primers were synthesisied on a Perkin Elmer 381A DNA Synthesiser, using the phosphoramidite method as recommended by the manufacturers. Nurse culture plates were prepared by 15 plating 2ml Of a cell suspension of Nicotiana bethiama on a petri dish containing 25 ml of MS salts, B5 vitamins (lmg L nicotinic acid, 1 mg L pyridoxine, lOmg L thiamine, 100 mg L inisitol) + 1 mg L 2-4D, 0.2 mg L BAP & 0.8% agar. The cells were swirled to cover the agar and then covered with 20 a sterile filter paper disc.
Selection media = MS basal media + 3% sucrose, 0.2 mg L IAA, 1 mg L BAP, 0.9% agar + 500 mg L cefotaxime & 100 mg L kanamycin.
25 The Loll sequence encoding the AFP, and a PRla apoplastic targeting sequence, were PCR amplified with 5 and

WO 99/37782

PCT/EP98/08553

3 oligonucleotide primers designed to generate the appropriate restriction sites to allow them to be ligated together at a BamHI site and the annealed product inserted into an NcoI/EcoRI opened pUC intermediate plasmid vector 5 (Messing 1983). The Loll AFP was separately inserted into three pUC vectors behind different promoter sequences (Granule bound starch synthase; cauliflower etched ring virus; double 35S cauliflower mosaic virus). They were then further cloned into a plant transformation binary vector 10 and introduced into tobacco using Agrobacteriim mediated transformation.
PCR reaction mixtures contained 5μl of xlO Taq rea ction buffer, lμl of dNTPs, lμl of 5 and 3 primers (50 pmol
15 μl), lμl of template Loll, 0, 5μl of Taq polymerase and 0.05μl of pfu proof reading enzyme. Tubes were overlayed with mineral oil and subjected to 30 cycles of 1 minute at 94°C, 1 minute at 55CC and 1 minute at 72°C after an initial denaturation step of 2 minutes at 94°C.
20
Digestions of PCR amplification products were carried out with the appropriate restriction enzymes in the recommended buffer (Boehringer Mannheim) for 16 hours at 37oC. Digestion mixtures were separated on a 1% agarose gel and
25 the relevant bands excised and purified using the Qiagen

WO 99/37782

PCT/EP98/08553

quick DNA gel purification kit following the manufacturers

recommendations.
Insert and plasmid vector were ligated with T4 ligase and 5 xlO buffer as recommended by Stratgene for 16 hours at 16C. Competent E.coli cells were transformed using 2μl of
ligation reaction, plated out and grown at 37oC overnight. Transformants were identified by PCR using specific 5 and 3 primers. Plasmid DNA was then isolated as described in 10 Maniatis Volume 1 and correct assembly confirmed by restriction digest analysis.
The HindIII/EcoRI inserts were excised and ligated as before into Hindlll/EcoRI digested general plant 15 transformation vector (GPTV). Competent E.coli were transformed-and transformants identified by PCR; subsequently isolated plasmid DNA was confirmed to be correct by sequencing.
20 The three different GPTV vectors were separately
transformed into Agrrobacterium tumafaciens (strain LBA 4404) using the freeze thaw method as described in the Plant Molecular Biology manual PMAN A3\7.
25 Nicotiana tabacum (var Petit Havana) seeds were surface

WO 99/37782

PCT/EP98/08553

sterilised for 10 minutes with a solution of 10% sodium hyperchlorite and after rinsing three times with distilled water, were transferred to Murashige. & Skoog basal medium + 3% sucrose +0.9% agar. The seeds were grown for two weeks 5 and then thinned to 2 per vessel after which sterile plantlets wer obtained by taking monthly shoot cuttings into MS basal medium + 3% sucrose + 0.9% agar. Agrobacterium cells containing the appropriate plasmid were cultured overnight.in Lennox broth (5g L-1 NaCl, 10 g IT1
10 yeast extract, 10 g L bacto tryptone and 15g L agar), after which they were recovered by centrifuging for 10 minutes at 3000 x g and resuspended in MS basal medium + 3% sucrose. Tobacco leaf discs cut with a sterile cork borer were infected by incubating for 10 minutes with the
15 Agrobacterium culture after which they were patted dry on sterile filter paper and plated face down on a nurse culture plate of tobacco cells.
The infected leaf discs were incubated at 26°C for 2 days 20 in a light intensity of 20001ux and then removed from the nurse culture plates to selection media They were then incubated at 3000 lux , 26*C, 16 hours day/ 8 hours dark and transferred every two weeks to fresh media. As new growing shoots appeared at the edge of the disc they were 25 removed to MS basal media + 3% sucrose , 500 mg L

WO 99/37782

PCT/EP98/08553

cefotaxime & 100 mg L kanamycin for rooting.
After rooting and growing to a size where they had 3-4 leaves a leaf from several lines of each construct plus 5 several untransformed control plants was removed for RI assay. The leaf tissue was ground in a eppendorf tube and the sap released was recovered by centrifugation. The sap was adjusted to 30% sucrose (w/v) prior to assay.
10 Several plant lines from each construct were demonstrated to have significant levels of ice recrystallisation inhibition activity. Extracts from each of the control plants possessed no activity. This clearly demonstrated that the Loll AFP had been transformed into tobacco, a
15 plant that does not have its own AFP, and was successfully expressed as an active protein with no need for cold acclimation.
Plants selected to be grown on, were potted into a 50% 20 perlite / 50 % peat mix and re-potted to flowering in a
26*C 16hour light / 22*C 8 hour dark cycle in a growth room.
Flowers were bagged to ensure self-pollination and seed collected and stored at +4oC.
25 Example IX

WO 99/37782

PCT/EP98/08553

To prove that the AFP of the invention does not require glycosylation to be active, the coding region was expressed in a prokaryote system. A strain of Escherichia Coli was created containing the Lolium AFP cDNA. 5
The Lolium cDNA was cloned into a pET32 plasmid from Novagen that contains thioredoxin for expression of the target gene as a fusion protein. All enzymes were from Boehringer Mannheim and used according to the manufacturers 10 instructions. Construction of expression plasraids,
transformation and growth of E.Coli were all as described in the Novagen pET system manual and Promega Applications guide.
15 The Lolium cDNA was cloned into the pET-32 plasmid as a PCR amplification fragment, with compatible restriction ends for ligation into the multiple cloning site of the pET-32 plasmid. This was produced using Lolium cDNA as the template and a 5' oligonucleotide primer
20 (TTTGCGCTCGAGTTAAGCGTCTGTCACGACTTTG and 3' oligonucleotide primer (TTTGCGCCATGGATGAACAGCCGAATACGATTTC). This introduced a Ncol restriction site at the 5' end and a Xhol restriction site at the 3' end of the amplification fragment. The reactions were carried out in a thermal
25 -cycler using Taq DNA polymerase for 25 cycles (denaturation at 94°C, annealing from 35°C to 60°C, expression at 72°C) . All subsequent PCR reactions were carried' out under the same conditions. The Ncol/Xhol PCR amplified fragment was then cloned into the Ncol/Xhol digested pET-32 plasmid and
30 transformed into competent non-expression E.Coli cells (strain XLl-Blue). After transformation, they were plated onto LB-ampicillin plates and grown at 37°C for 16 hours. 10 ampicillin resistant transformants were picked and analysed for integration of the Lolium cDNA by PCR using

WO 99/37782 PCT/EP98/08553
the pET upstream and downstream primers from Novagen.
Plasmid DNA was isolated from 3 positive transformants by miniprep and digested by Xhol and Ncol for transformation 5 into the competent expression E.Coli BL21(DE3) cells as described in the pET system manual. The transformed cells were plated onto LB-Ampicillin medium and incubated at 37°C for 24 hours together with a control made with non transformed BL21(DE3) E.C0Ii cells.
10 Three positive transformant colonies were selected and subcultured in LB-arapicillin media and incubated at 37°C for 1 hour to reached an O.D. (λ=600nm) of 0.6 and then inoculated in a larger medium volume and shaken at 37°C. When the O.D. reached 0.5, the cells were induced with IPTG
15 for protein expression for 3 hours as described in the pET system manual.
Expressed proteins were isolated from the E.Coli cells cytoplasm as described in the pET system manual; cells were
20 harvested by centr.ifiugati.on, resuspended in HEPES buffer (25mM HEPES, lOmM MgCl2, lOOmM NaCl, 1mM DTT, pH7.5) and sonicated for 10 seconds. The cytoplasmic protein fraction was centrifuged and the supernatant collected. An aliquot of the supernatant was adjusted to 30% sucrose and assayed
25 for ice recrystallisation inhibition activity as described in example III. The cytoplasmic protein extract demonstrated significant RI activity whereas the cytoplasmic protein extract produced in the same way from control E.Coli cells without the integrated Lolium cDNA had
30 no activity.
The fusion protein was purified by metal affinity column and the thioredoxin removed; by digestion with thrombin. The identity of the cleaved AFP was confirmed by potein

WO 99/37782

PCT/EP98/08553

sequencing of the N-terminus and this cleaved protein was shown to also have significant ice recrystallisation inhibition activity.
5 The above provides proof that the non-glycosylated Lolium perenne antifreeze protein expressed in E.Coli retained its recrystallisation inhibition activity, both as a fusion product with thioredoxin. and after thrombin, cleavage.

WE CLAIM:
1. A method of obtaining an anti-freeze protein (AFP) having the amino acid sequence D-E-Q-P-N-T-I-S-G-S-N-N-T-V-R-S-G-S-K-N-V-L-A-G-N-D-N-T-V-I-S-G-D-N-N-S-V-S-G-S-N-N-T-V-V-S-G-N-D-N-T-V-T-G-S-N-H-V-V-S-G-T-N-H-I-V-T-D-N-N-N-N-V-S-G-N-D-N-N-V-S-G-S-F-H-T-V-S-G-G-H-N-T-V-S-G-S-N-N-T-V-S-G-S-N-H-V-V-S-G-S-N-K-V-V-
T-D-A (SEQ ID NO: 1), or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, the method comprising: isolating the AFP from a plant.
2. A method according to Claim 1 wherein the plant is a cold-
acclimatised grass.
3. A method according to Claim 1 or 2 wherein the AFP has at least 90% overlap with SEQ ID NO: 1.
4. A method according to Claim 3 wherein the AFP has at least 95% overlap with the SEQ ID NO: 1.
5. A method according to any of Claims 1-4 wherein the plant is selected from a perennial grass such as Lolium perenne, Parapholis strigosa, Nardus stricta, Catapodium loliaceum and Lolium multiflorum, Poa trivialis, Poa pratensis, Holcus lanatus, Bromus sterilis and a cereal crop such as winter rye, winter wheat and winter barley.
6. A method according to any of Claims 1-5 wherein the plant is Lolium perenne, Poa trivialis, Holcus lanatus, or Bromus sterilis, or a combination thereof.

7. A method according to any of Claims 1-6 wherein isolating the AFP
comprises the steps of:
a) isolating an AFP-containing juice from the plant;
b) heat treating the plant or the AFP containing juice to a temperature of at least 60°C; and
c) removing the insoluble fraction from the AFP-containing juice,
wherein steps a) and b) can be performed in any order or simultaneously.
8. A method according to Claim 7 wherein the step of isolating the
AFP-containing juice from the plant comprises forming a slurry from the
plant or homogenising the plant.
9. A method according to Claim 8 wherein isolating the AFP-containing juice comprises filtering the juice from the slurry or the homogenate.
10. A method according to Claim 7 wherein the plant or the AFP-containing juice is heated to between 60°C and 110°C.
11. A method according to Claim 9 wherein the plant or the AFP-containing juice is heated to between 80°C and 105°C.
12. A method according to Claim 7 wherein the insoluble fraction is removed from the AFP-containing juice by filtration or precipitation.
13. A method according to any of Claims 7-12 further comprising a subsequent processing step of:
d) drying the AFP-containing juice to obtain an AFP-containing powder or paste; or

e) concentrating the AFP-containing juice to obtain an AFP-concentrate; or
f) separating the AFP from the AFP-containing juice.
14. A method according to Claim 13 wherein separating the AFP from
the AFP-containing juice is performed by chromatography.
15. A method of obtaining an AFP having the amino acid sequence of SEQ ID NO; 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, wherein the AFP is produced by a genetically modified organism.
16. A method according to Claim 15 comprising:

a) providing a polynucleotide that encodes the AFP, and
b) expressing the AFP from the polynucleotide in the organism.

17. A method according to Claim 15 or 16 wherein the AFP has at least 90% overlap with SEQ ID NO: 1.
18. A method according to Claim 17 wherein the AFP has at least 95% overlap with SEQ ID NO: 1.
19. A method according to Claim 15 or 16 wherein the polynucleotide that encodes the AFP has the sequence
GAT GAA CAG CCG AAT ACG ATT TCT GGG AGC AAC AAT ACT GTC AGA TCC GGG AGC AAA AAT GTT CTT GCT GGG AAT GAC AAC ACC GTC ATA TCT GGG GAC AAC AAT AGT GTG TCT GGG AGC AAC AAC ACT GTC GTA AGT GGG AAT GAC AAT ACC GTA

ACC GGC AGC AAC CAT GTC GTA TCA GGG ACA AAC CAT ATC GTT ACA GAC AAC AAC AAT AAC GTA TCC GGG AAC GAT AAT AAT GTA TCC GGG AGC TTT CAT ACC GTA TCC GGG GGG CAC AAT ACT GTG TCC GGG AGC AAC AAT ACC GTA TCT GGG AGC AAC CAC GTT GTA TCT GGA AGC AAC AAA GTC GTG ACA GAC GCT TAA(SEQ ID N0:2).
20. A method according to any of Claims 15 to 19 further comprising the
prior step of introducing the polynucleotide into the organism.
21. A method according to any of Claims 15-20 wherein the organism is
a microorganism or a plant.
22. A method according to Claim 21 wherein the microorganism is a yeast.
23. A method according to Claim 22 wherein the yeast is Pichia pastoris.
24. A method according to Claim 22 or 23 wherein the polynucleotide additionally encodes an α -factor signal sequence.
25. A method according to Claim 21 wherein the microorganism is a prokaryote.
26. A method according to Claim 25 wherein the prokaryote is Escherichia coli.

27. A method according to Claim 21 wherem the introduction of the polynucleotide into the plant comprises Agrobacterium mediated transformation.
28. A method according to Claim 21 or 27 wherein the plant is a Nicotania.
29. A method of constructing a nucleic acid vector capable of expressing an AFP having the amino acid sequence of SEQ ID NO: 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, in a suitable host organism, the method comprising:

a) providing a nucleic acid vector suitable for the host organism;
b) providing a polynucleotide that encodes the AFP;
c) optionally, providing a further polynucleotide that promotes expression or secretion of the AFP in the host organism, and
d) inserting the polynucleotide that encodes the AFP, and any further polynucleotide, into the nucleic acid vector.

30. A method according to Claim 29 wherein the AFP has at least 90% overlap with SEQ ID NO: 1,
31. A method according-to Claim 30 wherein the AFP has at least 95% overlap with SEQ ID NO: 1.
32. A method according to Claim 29 wherein the polynucleotide that encodes the AFP has the sequence of SEQ ID NO: 2.

41. A method according to Claim 40 wherein the yeast is Pichia pastoris
42. A method according to Claim 40 or 41 wherein the polynucleotide
also encodes an a-factor signal sequence.
43. A method according to Claim 39 wherein the host microorganism is
aprokaryote.
44. A method according to Claim 43 wherein the prokaryote is
Escherichia coli.
45. A method according to Claim 39 wherein the introduction of the polynucleotide into a host plant comprises Agrobacterium mediated transformation.
46. A method according to Claim 39 or 45 wherein the host plant is a Nicotania.
47. A method of making a food product containing an AFP having the amino acid sequence of SEQ ID NO: 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, wherein the food-product is genetically modified to produce the AFP.
48. A method of making a food product containing an AFP having the amino acid sequence of SEQ ID NO: 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified

33. A method according to any of Claims 29-32 wherein the suitable host organism is a yeast and wherein the further polynucleotide encodes an α-factor signal sequence.
34. A method according to any of Claims 29-32 wherein the suitable host organism is a plant and wherein the nucleic acid vector is suitable for Agrobacterium mediated transformation into the plant.
35. A method of obtaining a host organism capable of expressing an AFP having the amino acid sequence of SEQ ID NO: 1, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, the method comprising:

a) providing a polynucleotide that encodes the AFP, and
b) introducing the polynucleotide into the host organism.

36. A method according to Claim 35 wherein the AFP has at least 90% overlap with SEQ ID NO: 1.
37. A method according to Claim 36 wherein the AFP has at least 95% overlap with SEQ ID NO: 1.
38. A method according to Claim 35 wherein the polynucleotide that encodes the AFP has the sequence of SEQ ID NO: 2.
39. A method according to any of Claims 35-38 wherein the host organism is a microorganism or a plant.
40. A method according to Claim 39 wherein the host microorganism is a yeast.

versions thereof whereby said modification does not materially affect the ice recrystallisation properties, comprising adding the AFP to. the food-product
49. A method of making a polynucleotide that encodes an AFP having the amino acid sequence of SEQ ID NO: I, or having an amino acid sequence having at least 80% overlap with SEQ ID NO: 1, as well as modified versions thereof whereby said modification does not materially affect the ice recrystallisation properties, the method comprising synthesising or isolating a nucleic acid sequence that encodes the AFP.
Dated this 20th day of Jul y 2000.
M K CHAKRABARTI OF H V WILLIAMS & CO Agent for the applicant

Documents:

in-pct-2000-00201-mum-abstract(26-04-2005).doc

in-pct-2000-00201-mum-abstract(26-04-2005).pdf

in-pct-2000-00201-mum-cancelled pages(26-04-2005).pdf

in-pct-2000-00201-mum-claims(granted)-(26-04-2005).doc

in-pct-2000-00201-mum-claims(granted)-(26-04-2005).pdf

in-pct-2000-00201-mum-correspondence(ipo)-(19-10-2004).pdf

in-pct-2000-00201-mum-correspondence1(21-07-2000).pdf

in-pct-2000-00201-mum-correspondence2(06-10-2004).pdf

in-pct-2000-00201-mum-form 1a(20-07-2000).pdf

in-pct-2000-00201-mum-form 2(granted)-(26-04-2005).doc

in-pct-2000-00201-mum-form 2(granted)-(26-04-2005).pdf

in-pct-2000-00201-mum-form 3(20-07-2000).pdf

in-pct-2000-00201-mum-form 5(20-07-2000).pdf

in-pct-2000-00201-mum-form-pct-ipea-409(26-04-2005).pdf

in-pct-2000-00201-mum-form-pct-isa-210(26-04-2005).pdf

« Previous Patent

Next Patent »

Patent Number

207610

Indian Patent Application Number

IN/PCT/2000/00201/MUM

PG Journal Number

32/2007

Publication Date

10-Aug-2007

Grant Date

18-Jun-2007

Date of Filing

20-Jul-2000

Name of Patentee

HINDUSTAN LEVER LIMITED

Applicant Address

HINDUSTAN LEVER HOUSE, 165/166 BACKBAY RECLAMATION, MUMBAI 400 020, MAHARASHTRA, INDIA.

Inventors:

#	Inventor's Name	Inventor's Address
1	JARMAN, CARL DUDLEY	UNILEVER RESEARCH COLWORTH, COLWORTH HOUSE, SHARNBROOK, BEDFORD MK44 1LQ, UNITED KINGDOM.
2	SIDEBOTTOM, CHRISTOPHER MICHAEL	UNILEVER RESEARCH COLWORTH, COLWORTH HOUSE, SHARNBROOK, BEDFORD MK44 1LQ, UNITED KINGDOM.
3	TWIGG, SARAH	UNILEVER RESEARCH COLWORTH, COLWORTH HOUSE, SHARNBROOK, BEDFORD MK44 1LQ, UNITED KINGDOM.
4	WORRALL, DAWN	THE UNIVERSITY OF YORK, DEPARTMENT OF BIOLOGY, THE PLANT LABORATORY, HESLINGTON, YORK, Y01 5YW, UNITED KINGDOM.

PCT International Classification Number

C12 N 15/29

PCT International Application Number

PCT/EP98/08553

PCT International Filing date

1998-12-23

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	PCT/EP98/08553	1998-12-23	Australia